<SEC-DOCUMENT>0001564590-18-022451.txt : 20180829
<SEC-HEADER>0001564590-18-022451.hdr.sgml : 20180829
<ACCEPTANCE-DATETIME>20180829160019
ACCESSION NUMBER:		0001564590-18-022451
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181001
FILED AS OF DATE:		20180829
DATE AS OF CHANGE:		20180829
EFFECTIVENESS DATE:		20180829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				900772347
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38244
		FILM NUMBER:		181044345

	BUSINESS ADDRESS:	
		STREET 1:		1701 TRINITY STREET
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
		BUSINESS PHONE:		512-708-0155

	MAIL ADDRESS:	
		STREET 1:		1701 TRINITY STREET
		STREET 2:		SUITE 3.322
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78712
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>gnpx-def14a_20181001.htm
<DESCRIPTION>DEF 14A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
gnpx-def14a_20181001.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SCHEDULE 14A INFORMATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Proxy Statement Pursuant to Section 14(a) of the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filed by the Registrant? <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font> Filed by a Party other than the Registrant? <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Preliminary Proxy Statement</p></td></tr></table></div> <div></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Definitive Proxy Statement</p></td></tr></table></div> <div></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Definitive Additional Materials</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting Material Pursuant to &#167; 240.14a-12</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENPREX, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(Name of Registrant as Specified In Its Charter)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(Name of Person(s) Filing Proxy Statement If Other Than the Registrant)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of Filing Fee (Check the appropriate box)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">No fee required.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Title of each class of securities to which transaction applies:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Aggregate number of securities to which transaction applies:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="letter-spacing:-0.1pt;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Proposed maximum aggregate value of transaction:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Total fee paid:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fee paid previously with preliminary materials.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Amount Previously Paid:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Form, Schedule or Registration Statement No.:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filing Party:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Date Filed:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENPREX, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dell Medical Center, Health Discovery Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1701 Trinity Street, Suite 3.322, Austin, TX 78712</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gl3wrlsmluwf000001.jpg" title="" alt="" style="width:286px;height:64px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To Be Held On October 1, 2018</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Stockholder:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You are cordially invited to attend the 2018 annual meeting of stockholders (the &#8220;Annual Meeting&#8221;) of Genprex, Inc., a Delaware corporation (the &#8220;Company&#8221;). The meeting will be held on Monday, October 1, 2018 at 10:30 a.m. (local time) at the offices of W2O Group, 507 Calles Street, Suite 112, Austin, TX&nbsp;&nbsp;78702, for the following purposes:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance by the Company of shares of common stock pursuant to the terms of the private placement financing transaction contemplated by a Securities Purchase Agreement dated May 6, 2018, between the Company and each of the investors named therein, and the other documents and agreements related thereto, without giving effect to the caps on issuing shares contained therein.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">To elect the Class I director named herein to hold office until the 2021 annual meeting of stockholders.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">To ratify the selection by the Audit Committee of our Board of Directors of Daszkal Bolton LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">To conduct any other business properly brought before the meeting.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These items of business are more fully described in the Proxy Statement accompanying this Notice.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The record date for the Annual Meeting is August 21, 2018. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Order of the Board of Directors,</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rodney Varner</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rodney Varner</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austin, Texas</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 29, 2018</p> <div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">You are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy mailed to you, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENPREX, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dell Medical School, Health Discovery Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1701 Trinity Street, Suite 3.322, Austin, TX 78712</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROXY STATEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To Be Held On October 1, 2018</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Notice of Annual Meeting, this Proxy Statement and form of proxy are first being mailed on or about August 29, 2018 to all stockholders entitled to vote at the Annual Meeting.</p> <div></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;margin-right:1.07%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on October 1, 2018: The Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K are also available for viewing, printing, and downloading at the following website: <font style="text-decoration:underline;">www.proxydocs.com/GNPX</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE INFORMATION PROVIDED IN THE &#8220;QUESTION AND ANSWER&#8221; FORMAT BELOW IS FOR YOUR CONVENIENCE ONLY. YOU SHOULD READ THIS ENTIRE PROXY STATEMENT CAREFULLY.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How do I attend the Annual Meeting?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The meeting will be held on Monday, October 1, 2018 at 10:30 a.m. (local time) at the offices of W2O Group, 507 Calles Street, Suite 112, Austin, TX&nbsp;&nbsp;78702. Information on how to vote in person at the Annual Meeting is discussed below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Who can vote at the Annual Meeting?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Only stockholders of record at the close of business on August 21, 2018 will be entitled to vote at the Annual Meeting. On this record date, there were 15,037,944 shares of common stock issued and outstanding and entitled to vote, held by 132 holders of record.</p> <div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder of Record: Shares Registered in Your Name</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, on August 21, 2018, your shares were registered directly in your name with Genprex&#8217;s transfer agent, V Stock Transfer, LLC, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the proxy card that may be mailed to you, or vote by proxy over the telephone or on the internet as instructed below to ensure your vote is counted.</p> <div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Beneficial Owner: Shares Registered in the Name of a Broker or Bank</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>If, on August 21, 2018, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and this Proxy Statement and a voting instruction card are being forwarded to you by that organization. The </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">organization holding your account is considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owne</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What am I voting on?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are three matters scheduled for a vote:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Proposal 1: To approve for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance by the Company of shares of common stock (&#8220;Shares&#8221;), warrants (&#8220;Warrants&#8221;) to purchase shares of common stock and shares of common stock to be issued upon exercise of the Warrants (&#8220;Warrant Shares&#8221;) pursuant to the terms of the private placement financing transaction (&#8220; Private Placement&#8221;) contemplated by the Securities Purchase Agreement, dated May 6, 2018 (the &#8220;Securities Purchase Agreement&#8221;), between the Company and each of the investors named therein, and the other documents and agreements related thereto, without giving effect to the caps on issuing shares contained therein (the &#8220;Nasdaq 20% Issuance Proposal &#8221;);</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Proposal 2: To elect David E. Friedman as the Class I director to hold office until the 2021 annual meeting of stockholders; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Proposal 3: Ratification of the selection by the Audit Committee of our Board of Directors of Daszkal Bolton LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What if another matter is properly brought before the Annual Meeting?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy card to vote on those matters in accordance with their best judgment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How does the Board of Directors recommend I vote on the proposals?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board recommends a vote:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FOR the Nasdaq 20% Issuance Proposal;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FOR the election of David E. Friedman as the Class I director; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FOR the ratification of the section by the Audit Committee of the Board of Directors of Daszkal Bolton LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How do I vote?</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to the Nasdaq 20% Issuance Proposal, you may either vote &#8220;For&#8221; or &#8220;Against&#8221; or abstain from voting. With respect to the election of Mr. Friedman as the Class I director on the Board of Directors, you may either vote &#8220;For&#8221; Mr. Friedman to the Board or you may &#8220;Withhold&#8221; your vote for him. With respect to the ratification of the selection of Daszkal Bolton as the Company&#8217;s independent registered public accounting firm, you may vote &#8220;For&#8221; or &#8220;Against&#8221; or abstain from voting. The procedures for voting are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder of Record: Shares Registered in Your Name</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy over the telephone, vote by proxy through the internet or vote by proxy using the proxy card enclosed with this Proxy Statement. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by proxy.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">VOTE IN PERSON:</font> You may come to the Annual Meeting and we will give you a ballot when you arrive.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">VOTE BY PHONE:</font> To vote over the telephone, dial toll-free 866-356-9132 using any touch-tone telephone and follow the recorded instructions. You will be asked to provide the control number from the proxy card. Your telephone vote must be received by 11:59 p.m. Eastern Time on September 30, 2018 to be counted.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">VOTE BY INTERNET:</font> You may vote by completing an electronic proxy card at www.proxydocs.com/GNPX. You will be asked to provide the control number from the proxy card. Your internet vote must be received by 11:59 p.m. Eastern Time on September 30, 2018 to be counted.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">VOTE BY PROXY CARD:</font> To vote using a proxy card, simply complete, sign and date the proxy card enclosed with this Proxy Statement and return it promptly in the envelope we have provided or return it to Proxy Tabulator for Genprex, Inc., P.O. Box 8016, Cary, NC 27512-9903. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are a beneficial owner of shares registered in the name of your brokerage firm, bank, dealer or other agent, you should have received voting instructions from that organization rather than from Genprex. Simply follow the voting instructions provided by the organization to ensure that your vote is counted. Alternatively, you may vote by telephone or over the internet as instructed by your broker or bank. To vote in person at the Annual Meeting, you must obtain a valid proxy from your brokerage firm, bank, dealer or other agent. Follow the instructions from your broker or bank, or contact your broker or bank to request a proxy form.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How many votes do I have?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On each matter to be voted upon, you have one vote for each share of common stock you own as of the close of business on August 21, 2018.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">If I am a stockholder of record and I do not vote, or if I return a proxy card or otherwise vote without giving specific voting instructions, what happens?</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or in person at the Annual Meeting, your shares will not be voted.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq 20% Issuance Proposal, &#8220;For&#8221; the election of David E. Friedman as the Class I director and &#8220;For&#8221; the ratification of the selection by the Audit Committee of our Board of Directors of Daszkal Bolton LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.&nbsp;&nbsp;If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with voting instructions, what happens?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are a beneficial owner and do not instruct your brokerage firm, bank, dealer or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the particular proposal is considered to be a &#8220;routine&#8221; matter under applicable rules. Brokers and nominees can use their discretion to vote uninstructed shares with respect to matters that are considered to be routine under applicable rules, but not with respect to non-routine matters. Under applicable rules and interpretations, non-routine matters are matters that may substantially affect the rights or privileges of stockholders, including the Nasdaq 20% Issuance Proposal and elections of directors (even if not contested). Accordingly, without your instructions your broker or nominee may not vote your shares on Proposal 1 or Proposal 2, but may vote your shares on Proposal 3.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Who is paying for this proxy solicitation?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks, dealers or other agents for the cost of forwarding proxy materials to beneficial owners.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What if I Receive More Than One Proxy Card or Voting Instruction Form?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you hold your shares in multiple accounts or registrations, or in both registered and street name, you will receive a proxy card or voting instructions form for each account. Please sign, date and return all proxy cards you receive from the Company. If you choose to vote by proxy via the telephone or the internet, please vote once for each proxy card you receive. Only your latest dated proxy for each account will be voted. </p> <div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What if I have questions about my Genprex shares or need to change my mailing address?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may contact our transfer agent, V Stock Transfer, LLC, by telephone at (855) 9VSTOCK or, or by email at info@vstocktransfer.com if you have questions about your Company shares or need to change your mailing address.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Can I change my vote after submitting my proxy?</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder of Record: Shares Registered in Your Name</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">You may submit another properly completed proxy card with a later date.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">You may grant a subsequent proxy by telephone or through the internet.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">You may send a timely written notice that you are revoking your proxy to Genprex&#8217;s Secretary at Genprex, Inc., Dell Medical School, Health Discovery Building, 1701 Trinity Street, Suite 3.322, Austin, TX 78712.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy. Your most recent proxy card or telephone or internet proxy is the one that is counted.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If your shares are held by your brokerage firm, bank, dealer or other agent as a nominee, you should follow the instructions provided by your broker or bank.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">When are stockholder proposals and director nominations due for next year&#8217;s annual meeting?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be considered for inclusion in the Company&#8217;s proxy materials for next year&#8217;s annual meeting, your proposal must be submitted in writing by December 28, 2018.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you wish to submit a proposal (including a director nomination) that is not to be included in the Company&#8217;s proxy materials for next year&#8217;s annual meeting, you must do so not later than the close of business 90&#160;days, nor earlier than the close of business 120&#160;days, prior to the first anniversary of the date of the 2018 Annual Meeting. In the event the date of the 2019 annual meeting is more than 30&#160;days before or more than 30&#160;days after such anniversary date, notice must be delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th&#160;day prior to such annual meeting or the 10th&#160;day following the day on which public announcement of the date of such meeting is first made. You are also advised to review the Company&#8217;s amended and restated bylaws, which contain additional requirements relating to advance notice of stockholder proposals and director nominations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proposals should be addressed to:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genprex, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Corporate Secretary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dell Medical School, Health Discovery Building</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1701 Trinity Street, Suite 3.322</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Austin, TX 78712</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What are &#8220;broker non-votes&#8221;?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a beneficial owner of shares held in &#8220;street name&#8221; does not give instructions to the brokerage firm, bank, dealer or other agent holding the shares as to how to vote on matters deemed to be non-routine under applicable rules, the broker or nominee cannot vote the shares. These unvoted shares are counted as &#8220;broker non-votes.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How are votes counted</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> and how many votes are needed to approve each proposal</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">?</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Votes will be counted by the inspector of election appointed for the Annual Meeting, who will tabulate the votes at the Annual Meeting and will separately count:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">With respect to the Nasdaq 20% Issuance Proposal, votes &#8220;For&#8221; and &#8220;Against,&#8221; abstentions and broker non-votes; </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">With respect to the proposal to elect David E. Friedman as the Class I director, votes &#8220;For,&#8221; &#8220;Withhold&#8221; and broker non-votes; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">With respect to the proposal to ratify the Audit Committee&#8217;s selection of Daszkal Bolton LLP as our independent public accounting firm, votes &#8220;For&#8221; and &#8220;Against,&#8221; abstentions and broker non-votes. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The affirmative vote of the holders of a majority of the shares of our common stock present or represented by proxy and entitled to vote on the matter is required to approve the Nasdaq 20% Issuance Proposal.&nbsp;&nbsp;In addition, for Nasdaq purposes, the Nasdaq 20% Issuance Proposal requires approval by a majority of the votes cast at the meeting, provided that the investors in the Private Placement shall not be entitled to vote either the Shares owned by them or the Warrant Shares underlying Warrants owned by them, which are the Shares and Warrants to purchase our common stock that were issued to the investors pursuant to the Securities Purchase Agreement. If you mark your proxy as &#8220;Abstain&#8221; on the Nasdaq 20% Issuance Proposal, or if you give specific instructions that no vote be cast on any specific matter, the shares represented by that proxy will not be voted on that matter, but will count in determining whether a quorum is present. Broker non-votes have no effect toward the vote total for the Nasdaq 20% Issuance Proposal.&nbsp;&nbsp;Abstentions will have the effect of an &#8220;Against&#8221; vote on the Nasdaq 20% Issuance Proposal because abstentions are considered shares entitled to vote on this proposal.&nbsp;&nbsp;With respect to the Nasdaq 20% Issuance Proposal, if a stockholder is a beneficial owner of shares held in street name, such stockholder&#8217;s bank, broker or other nominee will not be permitted to vote such stockholder&#8217;s shares on the approval of the Nasdaq 20% Issuance Proposal unless the bank or broker receives voting instructions from such stockholder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the election of directors, the nominees receiving the most &#8220;For&#8221; votes from the holders of shares present in person or represented by proxy and entitled to vote on the election of directors will be elected.&nbsp;&nbsp;The only nominee for Class I director to be considered at the Annual Meeting is Mr. Friedman. Only votes &#8220;For&#8221; will affect the outcome of Proposal 2.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To be approved, the ratification of the selection of Daszkal Bolton LLP as the Company&#8217;s independent registered public accounting firm for its fiscal year ending December 31, 2018, must receive &#8220;For&#8221; votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. If you &#8220;Abstain&#8221; from voting, it will have the same effect as an &#8220;Against&#8221; vote. Broker non-votes, if any, will have no effect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in the way you would prefer, you <font style="text-decoration:underline;">must</font> provide voting instructions to your broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">What is the quorum requirement?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A quorum of stockholders is necessary to hold the Annual Meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the Annual Meeting in person or represented by proxy. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your brokerage firm, bank, dealer or other agent) or if you vote in person at the Annual Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to another date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">How can I find out the results of the voting at the Annual Meeting?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a Current Report on Form 8-K that we expect to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROPOSAL 1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ 20% ISSUANCE PROPOSAL</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Private Placement</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;9, 2018, we issued an aggregate of 828,500 shares of our common stock (the &#8220;Shares&#8221;) at a purchase price of $12.07 per share (the &#8220;Per Share Purchase Price&#8221;) and warrants to purchase up to 621,376 shares of our common stock (the &#8220;Warrants&#8221;) with an initial exercise price equal to $15.62 per share (the &#8220;Exercise Price&#8221;), in a private placement (the &#8220;Private Placement&#8221;) in accordance with a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) entered into with certain institutional and accredited investors (collectively, the &#8220;Purchasers&#8221;) on May&#160;6, 2018. The Per Share Purchase Price and the Exercise Price were subject to adjustment as described below. The total consideration paid to us in the Private Placement was approximately $10,000,000. When issued, the Warrants were exercisable on the earlier of six months from the issuance date or the date of effectiveness of the registration statement registering the underlying shares for resale, in each case subject to ownership limitations, and expire five years from such date. The Warrants are exercisable on a cashless basis six months after the issuance date if there is then no effective registration statement registering the resale of the shares underlying the Warrants. The $10,000,000 purchase price paid by the Purchasers on May 9, 2018 represents the entire purchase price that will be paid by the Purchasers for the Shares and the Warrants, even if additional Shares are issued and additional Warrant Shares become issuable following a Triggering Event discussed below. If the Warrants are exercised in full on a cash basis, we will receive an additional $9,705,893.</p> <div></div>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We engaged Maxim Group, LLC (&#8220;Maxim&#8221;) as our exclusive placement agent in connection with the Private Placement. Network 1 Financial Securities, Inc. served as an advisor in connection with the transaction.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>When the Shares and Warrants were issued, the Per Share Purchase Price of the Shares, the Exercise Price of the Warrants and the number of Warrant Shares were subject to adjustment based on the lowest volume weighted average price (&#8220;VWAP&#8221;) for the three trading days (the &#8220;VWAP Calculation&#8221;) immediately following each of the following events (&#8220;Triggering Events&#8221;): (i) the date that a registration statement covering the resale of the Shares issued in the Private Placement has been declared effective by the SEC, (ii) if a registration statement covering all Shares issued in the Private Placement is not declared effective, then the date that the Shares can be sold under Rule 144 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and (iii) if later than the dates set forth in (i) and (ii), then the date that our stockholders approve the Nasdaq 20% Issuance Proposal.&nbsp;&nbsp;Following a Triggering Event, the Per Share Purchase Price for the Shares would automatically be reduced, if applicable, to 85% of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lowest of the three VWAPs in the VWAP Calculation, and we </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be required to issue to the Purchasers additional Shares to reflect the adjustment to the P</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er Share Purchase Price so that the total number of Shares issued pursuant to the Securities Purchase Agreement </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equal $10,000,000 divided by the Per Share Purchase Price, as adjusted; provided that the Per Share Purchase Price </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be reduced to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> less than $4.25 per Share and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be adjusted upward.&nbsp;&nbsp; In addition, following a Triggering Event, the Exercise Price of the Warrants </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">automatically be reduced, if applicable, to 110% of the lowest of the three VWAPs in the VWAP Calculation; pr</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ovided, that in no event </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Exercise Price for the Warrants be reduced to less than $4.25 or increased as a result of an adjustment.&nbsp;&nbsp;In the event the Exercise Price of the Warrants </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adjusted, then the total number of Warrant Shares issuable upo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n exercise of the Warrants </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be increased so that the total exercise price payable to exercise the Warrants after the adjustment is equal to the total exercise price payable to exercise the Warrants before such adjustment</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As a result, the maximum numb</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er of securities that could be issued under the Securities Purchase Agreement is 2,352,940 Shares and Warrants to purchase an aggregate of 2,283,740 Warrant Shares, based on an adjusted Per Share Purchase Price of $4.25 per share and a Warrant Exercise Pri</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ce of $4.25 per share</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p> <div></div>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk521942396"></a>On May 22, 2018, our Registration Statement on Form S-1 (File No. 333-225090) (the &#8220;Registration Statement&#8221;) was filed with the Securities and Exchange Commission, or SEC, to register the resale of up to 2,352,940 Shares and up to 2,283,740 Warrant Shares. On July 26, 2018, the Registration Statement was declared effective by the SEC. As a result of the effectiveness of the Registration Statement, the Warrants became exercisable on July 26, 2018, subject to ownership limitations. <a name="_Hlk521942396"></a>The Per Share Purchase Price and the Warrant Exercise Price were both adjusted to $4.25 per share, based on a VWAP of $3.5299 on July 27, 2018. On August 1, 2018,  pursuant to the terms of the Securities Purchase Agreement and the Warrants, we issued to the Purchasers an aggregate of 1,174,440 additional Shares, and the Warrants became exercisable for a total of 2,283,740 Warrant Shares, with an exercise price equal to $4.25 per Warrant Share. An additional 350,000 Shares (i.e., the difference between 2,352,940 Shares and the sum of the Shares issued on May 9, 2018 and August 1, 2018) are issuable to one of the Purchasers in the Private Placement upon the request of such Purchaser under the terms of the Securities Purchase Agreement.</p> <div></div>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until stockholder approval of the Nasdaq 20% Issuance Proposal is obtained, the total number of Shares issuable pursuant to the Securities Purchase Agreement, plus the total number of Warrant Shares issuable upon exercise of the Warrants, shall not exceed 19.99% of the number of shares of our common stock outstanding immediately before the closing of the Private Placement. The 828,500 Shares initially issued to the Purchaser under the Securities Purchase Agreement and the 1,174,440 Shares issued on August 1, 2018 following the effectiveness of the Registration Statement, together constitute 13.29% of the number of shares of our common stock that were outstanding immediately before the closing of the Private Placement.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities issued pursuant to the Securities Purchase Agreement were issued under the exemption from registration provided by Section 4(a)(2) of the Securities Act and the rules and regulation promulgated thereunder, including Regulation D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Registration Rights</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Private Placement, we entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Purchasers. Pursuant to the Registration Rights Agreement, we agreed to prepare and file a registration statement (the &#8220;Resale Registration Statement&#8221;) with the SEC by May&#160;21, 2018 for purposes of registering the resale by the Purchasers of up to 2,352,940 Shares and up to 2,283,740 Warrant Shares. We also agreed to use our reasonable best efforts to cause the Resale Registration Statement to be declared effective by the SEC by June&#160;25, 2018 (or July 10, 2018 in the event of a full review by the SEC). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>The Registration Rights Agreement includes provisions for liquidated damages for failure to meet the specified filing and effectiveness deadlines or keep the Resale Registration Statement effective, subject to certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted exceptions. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Registration Rights Agreement, we have agreed to keep </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Resale R</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">egistration </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tatement effective at all times until the earlier of (i) the date as of which t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Investors may sell all of the securities covered by such registration statement without volume or manner-of-sale limitations pursuant to Rule 144 (or any successor thereto) promulgated under the Securities Act or (ii) the date on which the Investors sha</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll have sold all of the securities covered by </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Resale R</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">egistration </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tatement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 10, 2018, we filed with the SEC a Current Report on Form 8-K (the &#8220;Form 8-K&#8221;) that described the terms of the Private Placement.&nbsp;&nbsp;We filed as exhibits 4.1, 10.1 and 10.2 to the Form 8-K the form of Warrant, the Securities Purchase Agreement and the form of Registration Rights Agreement.&nbsp;&nbsp;We refer you to the Form 8-K and the exhibits thereto for a further description of the Private Placement.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Registration Statement was deemed filed on May 22, 2018, and was declared effective by the SEC on July 26, 2018. </p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nasdaq Rule 5635(d)</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Rule 5635(d) requires stockholder approval prior to an issuance of securities in connection with a transaction other than a public offering involving the sale, issuance or potential issuance by a company of common stock equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance for less than the greater of book and market value of our common stock as of the time of execution of the definitive agreement with respect to such transaction. The provisions in (i) the Securities Purchase Agreement that prevent the issuance of Shares if such issuance will result in such holders beneficially owning in excess of 19.99% of our common stock (the &#8220;Beneficial Ownership Limitation&#8221;) prior to stockholder approval and (ii) the Warrants that prevent exercise of the Warrants prior to stockholder approval to the extent the issuance of Warrant Shares pursuant to such exercise, when combined with the issuances of Shares pursuant to the Securities Agreement, would be in excess of the Beneficial Ownership Limitation, are both required under Nasdaq Rule 5635(d). We are seeking stockholder approval for the sale and issuance of such Shares and Warrant Shares in connection with the Private Placement pursuant to Nasdaq Rule 5635(d) without regard to the Beneficial Ownership Limitation.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Consequences if Stockholder Approval is Not Obtained</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not obtain approval of the Nasdaq 20% Issuance Proposal at the Annual Meeting, we are obligated under the Securities Purchase Agreement to call a stockholder meeting every four months thereafter to seek approval of the Nasdaq 20% Issuance Proposal from our stockholders until the earlier of the date such approval is obtained or the Warrants are no longer outstanding.&nbsp;&nbsp;In addition, so long as any Warrants are outstanding, we may not issue any capital stock or equity instruments in a capital raising transaction until we obtain stockholder approval of the Nasdaq 20% Issuance Proposal.&nbsp;&nbsp;If we do not obtain stockholder approval, the maximum number of shares that will be issuable pursuant to the Private Placement will not exceed 2,605,697 shares, which equals 19.99% of the number of outstanding shares of our common stock on May 5, 2018.</p> <div></div>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Proposal</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are seeking stockholder approval as required by Nasdaq Rule 5635(d) (as described above) to enable the us to issue a number of shares our common stock in connection with the Private Placement that exceeds 20% of the number of shares of our common stock that were outstanding before the Private Placement, which shares include the Shares issued pursuant to the Securities Purchase Agreement and the Warrant Shares issuable upon exercise of the Warrants, consisting of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a total of 2,352,940 Shares issuable pursuant to the Securities Purchase Agreement; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a total of 2,283,740 Warrant Shares issuable upon exercise of the Warrants.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Parties</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the sale and issuance of the Shares and the Warrants, the participants in the Private Placement have not had any material relationship with us within the past three years, other than Maxim, which served as the placement agent for the Private Placement, and Network 1 Financial Securities, Inc., which was the underwriter of our initial public offering and served as an advisor for the Private Placement.&nbsp;&nbsp;As compensation for serving as placement agent for the Private Placement, we paid to Maxim a fee of $700,000 and reimbursed Maxim&#8217;s related expenses.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vote Required</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The affirmative vote of the holders of a majority of the shares of our common stock present in person or represented by proxy and entitled to vote on the matter, excluding shares acquired in the Private Placement under the Securities Purchase Agreement, is necessary under Nasdaq Marketplace Rule 5635(e)(4) to approve the Nasdaq 20% Issuance Proposal. Broker non-votes will not affect whether this proposal is approved, but abstentions will have the same effect as a vote against the proposal.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In accordance with applicable Nasdaq Marketplace Rules, holders of the shares of our common stock purchased in the Private Placement are not entitled to vote such shares on the Nasdaq 20% Issuance Proposal.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the closing of the Private Placement, and as a condition to such closing, certain of our stockholders entered into voting agreements with the Purchasers. As of immediately prior to the closing of the Private Placement, the stockholders executing the voting agreements owned approximately 62% of our total issued and outstanding common stock. Pursuant to the voting agreements, the stockholder signatories agreed to vote all shares of our common stock owned by them in favor of the Nasdaq 20% Issuance Proposal.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential Effects of this Proposal</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of the shares of our common stock which are the subject of the Nasdaq 20% Issuance Proposal will result in an increase in the number of shares of common stock outstanding. This will result in a decrease to the respective ownership and voting percentage interests of stockholders prior to the Private Placement. The market value of our Company and our future earnings may be reduced.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as described above under &#8220;Registration Rights,&#8221; we have registered the securities issued in the Private Placement, which includes a total of 4,636,680 shares of our common stock, consisting of a maximum of 2,352,940 Shares issued or issuable pursuant to the Securities Purchase Agreement and 2,283,740 Warrant Shares that could become issuable upon exercise of Warrants. The release of up to 4,636,680 freely traded shares onto the market, or the perception that such shares will or could come onto the market, has had and could have an adverse effect on the trading price of our stock.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have broad discretion to use the net proceeds to us from the sale of such shares, including the proceeds received upon exercise of the Warrants, and you will be relying solely on the judgment of our Board of Directors and management regarding the application of these proceeds. Our use of the proceeds may not improve our operating results or increase the value of your investment.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For your consideration of the Nasdaq 20% Issuance Proposal, a description of the material terms of the Private Placement is set forth in this proxy statement to provide you with basic information concerning the Private Placement. However, the description above is not a substitute for reviewing the full text of the referenced documents, which were attached as exhibits to our Current Report on Form 8-K as filed with the SEC on May 10, 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE APPROVAL OF THE NASDAQ 20% ISSUANCE PROPOSAL.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROPOSAL 2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ELECTION OF CLASS I DIRECTOR</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board of Directors is divided into three classes. Each class consists of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board presently has three members. There is one Class I director, David E. Friedman, whose term of office expires in 2018. Proxies may not be voted for a greater number of persons than the one nominee, Mr. Friedman, named in this proxy statement. Mr. Friedman, a current director of the Company, was recommended for nomination to the Board at the Annual Meeting by the Nominating and Corporate Governance Committee of the Board. If elected at the Annual Meeting, Mr. Friedman would serve until the 2021 annual meeting of stockholders and until his successor has been duly elected and qualified, or, if sooner, until his death, resignation or removal. It is the Company&#8217;s policy to invite directors and nominees for director to attend the Annual Meeting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. Accordingly, the nominee receiving the highest number of affirmative votes will be elected. The only nominee for Class I director to be considered at the Annual Meeting is Mr. Friedman. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of Mr. Friedman. If Mr. Friedman becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will instead will be voted for the election of a substitute nominee proposed by the Company. Mr. Friedman has agreed to serve if elected. The Company&#8217;s management has no reason to believe that Mr. Friedman will be unable to serve.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nominee</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nominating and Corporate Governance Committee seeks to assemble a Board that, as a whole, possesses the appropriate balance of professional and industry knowledge, financial expertise and high-level management experience necessary to oversee and direct the Company&#8217;s business. To that end, the Nominating and Corporate Governance Committee has identified and evaluated nominees in the broader context of the Board&#8217;s overall composition, with the goal of recruiting members who complement and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities that the Nominating and Corporate Governance Committee views as critical to effective functioning of the Board. The biographies below include information, as of the date of this Proxy Statement, regarding the specific and particular experience, qualifications, attributes or skills of each director or nominee that led the Nominating and Corporate Governance Committee to believe that that nominee should continue to serve on the Board. However, each member of the Nominating and Corporate Governance Committee may have a variety of reasons why he believes a particular person would be an appropriate nominee for the Board, and these views may differ from the views of other members.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nominee for Election for a Three-</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Y</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ear Term Expiring at the 2021 Annual Me</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">eting</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">David E. Friedman<font style="font-style:normal;">, 55, has served as a member of our Board since August 2012. Since August 2010, Mr.&#160;Friedman has served as a partner of TCG Group Holdings, an Austin, Texas based&#160;SEC-registered&#160;investment advisor to separately-managed institutional and private client accounts. In addition, since January 2012, Mr.&#160;Friedman has served as a managing partner of ACM Investment Management, which manages hedge fund assets acquired from KeyCorp, the bank holding company parent of KeyBank. From 2006 to 2010, Mr.&#160;Friedman served as the Chief Operating Officer of Austin Capital Management, which was owned by KeyCorp, where he led the company&#8217;s&#160;non-investment&#160;functions, including all legal, finance, investor relations, technology and operations teams. Before joining Austin Capital, Mr.&#160;Friedman was a Director on the Global Prime Brokerage desk of Citigroup in New York, and an associate at the law firm of Proskauer Rose in its New York headquarters. Mr.&#160;Friedman received his BS in management from Tulane University and his JD from Duke University School of Law. He is admitted to the Bar of the State of New York and holds FINRA Series 4, 7, 24 and 63 securities registrations. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Nominating and Corporate Governance Committee and Board believe that Mr.&#160;Friedman&#8217;s unique and valuable mix of high-level and relevant finance, legal and operations experience makes him a well-rounded business leader and a valuable member of our Board.<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE BOARD OF DIRECTORS RECOMMENDS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THAT STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ELECTION OF MR. FRIEDMAN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS THE CLASS I DIRECTOR.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Continuing in Office Until the 2019 Annual Meeting</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Robert W. Pearson<font style="font-style:normal;">, 56, has served as a member of our Board since July 2012. In June 2009, Mr.&#160;Pearson joined W2O Group, a global network of complementary marketing, communications, research and development firms, and has held a number of senior positions at W2O Group, including Chief Technology Officer, President and since February 2017, Vice Chair and Chief Innovation Officer. From March 2012 to February 2017, Mr.&#160;Pearson served as President of W2O, and from June 2009 to March 2012 as its Chief Technology&#160;&amp; Media Officer. From 2007 to 2009, Mr.&#160;Pearson served as Dell Inc.&#8217;s Vice President, Communities and Conversations, and before that as its Vice President, Corporate Group Communications. From 2003 to 2006, Mr.&#160;Pearson served as Head of Global Corporate Communications and as Head of Global Pharma Communications at Novartis Pharmaceuticals, where he also served on the Pharma Executive Committee. Before joining Novartis, Mr.&#160;Pearson served as President, The Americas and Chair, Healthcare Practice for GCI Group, a global public relations consultancy, and was responsible for creating and building the firm&#8217;s global healthcare practice. Mr.&#160;Pearson previously served as Vice President of Media and Public Affairs at Rhone-Poulenc Rorer, or RPR (now Sanofi-Aventis) and worked at RPR and Ciba-Geigy in communications and pharmaceutical field sales. Mr.&#160;Pearson holds a BA from the University of North Carolina at Greensboro and an MBA from Fairleigh Dickinson University. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Nominating and Corporate Governance Committee and Board believe that Mr.&#160;Pearson&#8217;s senior management experience at international pharmaceutical companies and public relations/ investor relations firms, as well as with start-up businesses, and his knowledge and personal contacts in the pharmaceutical industry, and his business management acumen, make him a valuable member of our Board.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Continuing in Office Until the 2020 Annual Meeting</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">J. Rodney Varner, <font style="font-style:normal;">61, is a&#160;co-founder&#160;of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. Mr.&#160;Varner also served as our President until April&#160;10, 2018. Mr.&#160;Varner served as a partner of the law firm Wilson&#160;&amp; Varner, LLP, since 1991. Mr.&#160;Varner has more than thirty-five years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr.&#160;Varner has represented&#160;for-profit&#160;and&#160;non-profit&#160;companies at the Board or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr.&#160;Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr.&#160;Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. Mr.&#160;Varner received his BBA, with high honors, from Texas A&amp;M University and his J.D. from The University of Texas School of Law.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Nominating and Corporate Governance Committee and Board believe that Mr. Varner&#8217;s broad legal experience, as well as his position of Chief Executive Officer of the Company, qualifies him to serve as a member of our Board.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Independence of the Board of Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the listing requirements and rules of The Nasdaq Capital Market, independent directors must constitute a majority of a listed company&#8217;s Board within 12 months after its initial public offering. In addition, the rules of The Nasdaq Capital Market require that, subject to specified exceptions and&#160;phase-in&#160;periods following its initial public offering, each member of a listed company&#8217;s audit, compensation and nominating and governance committee be independent, and that a listed company&#8217;s audit committee must have at least three members and a listed company&#8217;s compensation committee must have at least two members. Under the rules of The Nasdaq Capital Market, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to rely on the&#160;phase-in&#160;rules of The Nasdaq Capital Market with respect to the independence of our Board and the Audit Committee. In accordance with these&#160;phase-in&#160;provisions, our Board and the Audit, Compensation, and Nominating and Corporate Governance Committees have at least two independent members, and all members will be independent within one year of the effective date of the registration statement relating to the initial public offering of our common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit committee members must also satisfy independence criteria set forth in Rule&#160;10A-3&#160;under the Exchange Act, or Rule&#160;10A-3.&#160;To be considered to be independent for purposes of Rule&#160;10A-3,&#160;a member of an audit committee of a listed company may not, other than in his or her capacity as a member of a company&#8217;s audit committee, the company&#8217;s Board or any other board committee: (1)&#160;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has undertaken a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provided by each director concerning his</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">background, employment and affiliations, including family relationships, our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has determined that other than Rodney Varner, our CEO who serves on the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as the Chairman, each of our directors does not have </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the applicable rules and regulations of the lis</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ting requirements and rules of The Nasdaq Capital Market and under the applicable rules and regulations of the SEC. In making this determination, our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> considered the current and prior relationships that each&#160;non-employee</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">director has with us and all o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ther facts and circumstances our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each&#160;non-employee&#160;director.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board Leadership Structure</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Executive Officer, Rodney Varner, also currently serves as the Chairman of our Board. The Board does not currently have a lead independent director. We believe that the leadership structure of our Board is appropriate at the present time, in light of the small size of our Board. We believe that the fact that two of the three members of the Board are independent reinforces the independence of the Board in its oversight of our business and affairs, and provides for objective evaluation and oversight of management&#8217;s performance, as well as management accountability. In addition, we have a separate chair for each committee of the Board. The chair of each committee is expected to report to the Board from time to time, or whenever so requested by the Board, on the activities of his committee in fulfilling its responsibilities as detailed in its respective charter or specify any shortcomings should that be the case. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Role of the Board in Risk Oversight</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee of our Board is primarily responsible for overseeing our risk management processes on behalf of our Board. Going forward, we expect that the Audit Committee will receive reports from management on at least a quarterly basis regarding our assessment of risks. In addition, the Audit Committee reports regularly to our Board, which also considers our risk profile. The Audit Committee and our Board focus on the most significant risks we face and our general risk management strategies. While our Board oversees our risk management, management is responsible for&#160;day-to-day&#160;risk management team processes.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Meetings of the Board of Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board met three times and acted by unanimous written consent four times during 2017. All directors attended at least 75% of the aggregate number of meetings of the Board during 2017. The Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee did not meet in 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2017, in anticipation of our initial public offering, which occurred on March 29, 2018, our Board established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. Our Board may establish other committees to facilitate the management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our Board.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Audit Committee consists of David Friedman and Robert Pearson. The chair of our Audit Committee is Mr.&#160;Friedman, who our Board has determined is an &#8220;audit committee financial expert&#8221; as that term is defined by the SEC rules implementing Section&#160;407 of the Sarbanes-Oxley Act, and possesses financial sophistication, as defined under the listing standards of The Nasdaq Capital Market. Our Board has also determined that each member of our Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board has examined each Audit Committee member&#8217;s scope of experience and the nature of their experience in the corporate finance sector. The Board has adopted a written Audit Committee charter that is available to stockholders on the Company&#8217;s website at<font style="text-decoration:underline;"> www.genprex.com. </font>The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report on Form 10-K for the year ended December 31, 2017. The Audit Committee did not meet during the year ended December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The responsibilities of our Audit Committee include:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">discussing our risk management policies;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and approving or ratifying any related person transactions; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">preparing the Audit Committee report required by SEC rules.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of the Audit Committee of the Board of Directors*</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2017 with management of the Company.&nbsp;&nbsp;The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Auditing Standard No. 1301, Communications with Audit Committees, as adopted by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;). The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent registered public accounting firm's communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm&#8217;s independence. Based on the foregoing, the Audit Committee has recommended to the Board that the audited financial statements be included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:61.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David E. Friedman (Chair) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:61.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert W. Pearson</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">* The material in this report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference in any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Compensation Committee consists of David Friedman and Robert Pearson. The chair of our Compensation Committee is Mr. Pearson. The Board has adopted a written Compensation Committee charter that is available to stockholders on the Company&#8217;s website at<font style="text-decoration:underline;"> www.genprex.com. </font>The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report on Form 10-K for the year ended December 31, 2017. The Compensation Committee did not meet during the year ended December 31, 2017. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The responsibilities of our Compensation Committee include:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and approving, or recommending that our Board approve, the compensation of our chief executive officer and our other executive officers;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and recommending to our Board the compensation of our directors;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">selecting independent compensation consultants and advisers and assessing whether there are any conflicts of interest with any of the committee&#8217;s compensation advisers; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and approving, or recommending that our Board approve, incentive compensation and equity plans.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation Committee Processes and Procedures</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Compensation Committee discusses and makes recommendations to the Board for annual compensation adjustments, annual bonuses, annual equity awards, and corporate performance objectives. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee by the Chief Executive Officer.&nbsp;&nbsp;In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which determines recommendations to the Board regarding any adjustments to his compensation as well as awards to be granted. The Chief Executive Officer does not participate in, and is not present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels, compensation data from comparative companies, compensation surveys, and recommendations of any compensation consultant, if applicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under its charter, the Compensation Committee has the authority to obtain, at the expense of the Company, advice and assistance from internal and external legal, accounting or other advisers and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any advisers engaged for the purpose of advising the Compensation Committee. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Company engaged Longnecker &amp; Associates (&#8220;Longnecker&#8221;) as its compensation consultant. Longnecker was retained to provide an assessment of the Company&#8217;s executive and director compensation programs in comparison to executive and director compensation programs at selected publicly-traded peer companies. As part of its engagement, Longnecker was requested by the Compensation Committee to develop the peer group of comparative companies and to perform analyses of compensation levels for that group. Longnecker developed peer group and related recommendations that were presented to the Compensation Committee for its consideration.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nominating and Corporate Governance Committee</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Nominating and Corporate Governance Committee consists of David Friedman and Robert Pearson. The chair of our Nominating and Corporate Governance Committee is Mr. Friedman. The Board has adopted a written Nominating and Corporate Governance Committee charter that is available to stockholders on the Company&#8217;s website at<font style="text-decoration:underline;"> www.genprex.com. </font>The information on our website is not incorporated by reference into this Proxy Statement or our Annual Report on Form 10-K for the year ended December 31, 2017. The Nominating and Corporate Governance Committee did not meet during the year ended December 31, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The responsibilities of our Nominating and Corporate Governance Committee include:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">identifying individuals qualified to become members of our Board;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">recommending to our Board the persons to be nominated for election as directors and for appointment to each of the board&#8217;s committees;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reviewing and making recommendations to our Board with respect to management succession planning;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developing and recommending to our Board corporate governance principles; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">overseeing a periodic evaluation of our Board.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nominating and Corporate Governance Committee does not set specific criteria for directors but seeks individuals who have the ability to read and understand basic financial statements, the highest personal integrity and ethics, relevant expertise upon which to be able to offer advice and guidance to management, sufficient time to devote to the affairs of the Company, the ability to exercise sound business judgment and the commitment to rigorously represent the long-term interests of the Company&#8217;s stockholders. The Nominating and Corporate Governance Committee may modify these qualifications from time to time.&nbsp;&nbsp;Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders.&nbsp;&nbsp;In conducting this assessment, the Nominating and Corporate Governance Committee considers diversity, age, skills and such other factors as it deems appropriate to maintain a balance of knowledge, experience and capability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary.&nbsp;&nbsp;The Nominating and Corporate Governance Committee then uses its network of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm.&nbsp;&nbsp;The Nominating and Corporat</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Governance Committee conducts </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any appropriate and necessary inquiries into the backg</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rounds and qualifications of possible candidates after considering the function and needs of the Board.&nbsp;&nbsp;The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then selects candidates for recommen</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dation to the Board by majority vote.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to alter the manner in which it evaluates candidates based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee at the following address: c/o Genprex, Inc., Dell Medical School, Health Discovery Building, 1701 Trinity Street, Suite 3.322, Austin, TX 78712, Attn: Secretary,&nbsp;&nbsp;no later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting. In the event the date of the annual meeting is more than 30&#160;days before or more than 30&#160;days after such anniversary date, notice must be delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th&#160;day prior to such annual meeting or the 10th&#160;day following the day on which public announcement of the date of such meeting is first made. Submissions must include the name and address of the Company stockholder on whose behalf the submission is made; the number of Company shares that are owned beneficially by such stockholder as of the date of the submission; the full name of the proposed candidate; a description of the proposed candidate&#8217;s business experience for at least the previous five years; complete biographical information for the proposed candidate; and a description of the proposed candidate&#8217;s qualifications as a director. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board has adopted a formal process by which stockholders may communicate with the Board or any of its directors. Stockholders who wish to communicate with the Board may do so by sending written communications addressed to the Secretary of Genprex, Inc., Dell Medical School, Health Discovery Building, 1701 Trinity Street, Suite 3.322, Austin, TX 78712. These communications will be reviewed by the Secretary of Genprex, who will determine whether the communication is appropriate for presentation to the Board or the relevant director. The purpose of this screening is to allow the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROPOSAL 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RATIFICATION OF SELECTION OF </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee has selected Daszkal Bolton LLP as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2018 and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Daszkal Bolton has audited the Company&#8217;s financial statements since 2012. Representatives of Daszkal Bolton are not expected to be present at the Annual Meeting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>Neither the Company&#8217;s amended and restated bylaws nor other governing documents or law require stockholder ratification of the selection of Daszkal Bolton as the Company&#8217;s independent registered public accounting firm. However, the Audit Committee is submitting the selection of Daszkal Bolton to the stockholders </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for ratification as a matter of good corporate practice. If the stockholders fail to ratify the s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">election, the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will reconsider whether or not to retain that firm. Even if the selection is ratified, the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in its discretion may direct the appointment of different independent auditors at any time during the year if they dete</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rmine that such a change would be in the best interests of the Company and its stockholders.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote on the matter at the Annual Meeting will be required to ratify the selection of Daszkal Bolton.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principal Accountant Fees and Services</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fees billed by Daszkal Bolton LLP for audit, audit-related, tax and all other services rendered for 2017 and 2016:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fee Category</p></td>
<td valign="bottom"  style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$75,333</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23,000</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-Related Fees</p></td>
<td valign="bottom"  style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">--</p></td>
<td valign="bottom"  style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">--</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,400</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,300</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Other Fees</p></td>
<td valign="bottom"  style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">--</p></td>
<td valign="bottom"  style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,000</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:65.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Fees</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$78,733</p></td>
<td valign="bottom"  BGCOLOR="#C6D9F1" style="width:17.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33,300</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a>Audit Fees.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Audit fees consist of fees billed for the audit of our annual consolidated financial statements, the review of the interim consolidated financial statements, and related services that are normally provided in connection with registration statements, including the registration statement for our initial public offering. Included in the 2017 audit fees is $31,100 of fees billed in connection with our initial public offering in April 2018.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Fees.<font style="font-style:normal;">&#160;&#160;&#160;&#160;Tax fees consist of aggregate fees for tax compliance and tax advice, including the review and preparation of our various jurisdictions' income tax returns.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors pre-approved all services performed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the audit of the 2017 financial statements, the Company entered into an engagement agreement with Daszkal Bolton, LLP that sets forth the terms on which Daszkal Bolton would perform audit services for the Company. That agreement is subject to alternative dispute resolution procedures.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pre-Approval Policies and Procedures</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee has adopted a policy for the pre-approval of audit and non-audit services rendered by the Company&#8217;s independent registered public accounting firm, Daszkal Bolton. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee&#8217;s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pre-approval of services may be delegated to one or more of the Audit Committee&#8217;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has determined that the rendering of services other than audit services by </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daszkal Bolton </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is compatible with maintaining the principal accountant</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s independence.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#8220;FOR&#8221;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE RATIFICATION OF THE SELECTION OF DASZKAL BOLTON LLP</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS THE COMPANY&#8217;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE FISCAL YEAR ENDING DECEMBER 31, 2018</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE OFFICERS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">J. Rodney Varner&#160;<font style="font-weight:normal;font-style:normal;">is a&#160;co-founder&#160;of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. For additional information about Mr. Varner&#8217;s experience and education, see above under &#8220;Director Continuing in Office until the 2020 Annual Meeting.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Julien L. Pham, MD, MPH<font style="font-weight:normal;font-style:normal;">, 41, has served as our Chief Operating Officer since October 2016 and as our President since April&#160;10, 2018. In March 2013, Dr.&#160;Pham&#160;co-founded&#160;RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases, and served as its Chief Medical Officer from March 2013 to September 2016. Prior to&#160;co-founding&#160;RubiconMD, Dr.&#160;Pham served on the faculty at Harvard Medical School&#8217;s Brigham and Women&#8217;s Hospital, where he joined as a fellow in July 2008 and became an Associate Physician in the Division of Nephrology in August 2011. Dr.&#160;Pham has over fifteen years of leadership experience in clinical settings and in emerging medical technology companies. During this time, he has held various research and teaching positions including Chief Residency in Internal Medicine and Pediatrics at the University of Illinois at Chicago Medical Center, and has received multiple awards including excellence in teaching awards from AOA and Harvard Medical School. He is a board-certified internal medicine doctor and nephrologist. Dr.&#160;Pham has received NIH research funding for translational research while at Harvard Medical School, and he has published in basic science, translational, and health policy fields. He holds a BS in Cell and Molecular Biology from University of Washington and received his MD from the University of Washington School of Medicine and his MPH at the Harvard School of Public Health.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ryan M. Confer&#160;<font style="font-weight:normal;font-style:normal;">37, has served as our Chief Financial Officer since September 2016. From December 2013 through September 2016, he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr.&#160;Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr.&#160;Confer has over ten years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for&#160;non-profit&#160;and&#160;for-profit&#160;entities since 2008. Mr.&#160;Confer has also served as an international business development consultant for the University of Texas at Austin&#8217;s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Mr.&#160;Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of Mr.&#160;Varner, Dr.&#160;Pham and Mr.&#160;Confer is currently a full-time employee of Genprex. Mr.&#160;Varner spends fewer than 10 hours per month on duties relating to Wilson&#160;&amp; Varner, LLP; Dr.&#160;Pham spends fewer than 10 hours per month in continuing medical practice to comply with licensing requirements; and Mr.&#160;Confer spends fewer than 10 hours per month providing financial consulting services to other companies that are not competitive with us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company&#8217;s directors, executive officers, and persons who own more than ten percent (10%) of a registered class of the Company&#8217;s equity securities, to file initial reports of ownership and reports of changes in ownership of Common Stock and other equity securities of the Company with the SEC. Officers, directors and stockholders holding more than ten percent (10%) of the outstanding capital stock of the Company are required by SEC regulations to furnish the Company with copies of all Section 16(a) reports they file.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fiscal year ended December 31, 2017, the Company was not subject to the requirements of Section 16(a) of the Exchange Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITY OWNERSHIP OF</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth certain information available to us with respect to the beneficial ownership of our common stock as of August 1, 2018, by:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of any class of our voting securities;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">each of our directors;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">each of our named executive officers; and </p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">all of our current executive officers and directors as a group.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table lists applicable percentage ownership based on 15,037,944 shares of common stock outstanding as of August&#160;1, 2018. Options and warrants to purchase shares of our common stock that are exercisable within 60&#160;days of August1, 2018, are deemed to be beneficially owned by the persons holding these options for the purpose of computing percentage ownership of that person, but are not treated as outstanding for the purpose of computing any other person&#8217;s ownership percentage. </p> <div></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise noted below, the address for each person or entity listed in the table is c/o Genprex, Inc., Dell Medical School, Health Discovery Building, 1701 Trinity Street, Suite 3.322, Austin, Texas 78712.</p> <div></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="bottom"  style="width:26.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Beneficially Owned</p></td>
</tr>
<tr>
<td valign="top"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Beneficial Owner</font></p></td>
<td valign="bottom"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Number</font></p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Percentage</font></p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5% or Greater Stockholders</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christy Mallinson Nance(1)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,167,694</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.8%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jack A. Roth, MD, FACS(2)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,393,853</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Viet-An Hoan Ly and affiliated entities(3)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294,760</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texas Treasury Safekeeping Trust Company(4)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,235,219</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sabby Volatility Master Fund, Ltd.(5)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">755,070</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.99%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hudson Bay Master Fund, Ltd.(6)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,542,140</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.99%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors and Named Executive Officers</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">J. Rodney Varner(7)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,794,459</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.8%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Julien Pham(8)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,008</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Confer(9)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,008</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David E. Friedman(10)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,111</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert W. Pearson(11)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,111</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:73.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All current executive officers and directors as a group (5 persons)(7)(8)(9)(10)(11)</p></td>
<td valign="middle"  style="width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,052,736</p></td>
<td valign="top"  style="width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:12.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.0%</p></td>
<td valign="top"  style="width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.07%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents beneficial ownership of less than 1%.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 2,956,298 shares of common stock held by Domecq Sebastian, LLC and 161,396 shares of common stock that Domecq Sebastian, LLC has the right to acquire from us within 60 days of August&#160;1, 2018 pursuant to the exercise of stock options. Domecq Sebastian, LLC is affiliated with David Nance, a former director and officer who is now deceased. Christy Mallinson Nance holds voting and dispositive power of the securities held by Domecq Sebastian, LLC. The address of Domecq Sebastian, LLC is 8203 Scenic Ridge Cove, Austin, Texas 78735.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 1,338,999 shares of common stock held by JREG Investments, Ltd. and 5,000 shares of common stock that Dr. Roth has the right to acquire from us within 60 days of August 1, 2018, pursuant to a consulting agreement between Dr. Roth and us. Dr.&#160;Roth holds voting and dispositive power over the shares held by JREG Investments, Ltd. The address of JREG Investments, Ltd. and of Dr.&#160;Roth is 6516 Brompton Road, Houston, Texas 77005.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes (a) 583,008 shares of common stock held by Inception Fund LP, (b) 475,974 shares of common stock held by Tangletrade Fund LP, (c) 102,000 shares of common stock held by Inception Incubator Limited, (d) 3,154 shares of common stock held by Blackbox Data LLC, (e) 9,023 shares of common stock held by New Path Mining LLC, (f) 542,656 shares of common stock that&#160;Inception Fund, LP has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of a warrant, (g) 497,130 shares of common stock that Tangletrade Fund LP has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of a warrant, (h) 25,000 shares of common stock that Inception Incubator Limited has the right to acquire from us within 60 days of August 1, 2018,  and (h) 56,815 shares of common stock that Mr.&#160;Ly has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options.&#160;Viet-An&#160;Hoan Ly holds voting and dispositive power over the shares held by Inception Fund LP, Tangletrade Fund LP, Inception Incubator Limited, Blackbox Data LLC and New Path Mining LLC. The address of each of these entities and of Mr.&#160;Ly is 5400 Carillon Point Road, Building 5000, Kirkland, Washington 98033.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Paul Ballard, the Chief Executive Officer of the Texas Treasury Safekeeping Trust Company, holds voting and dispositive power of the securities held by the Texas Treasury Safekeeping Trust Company. The address of the Texas Treasury Safekeeping Trust Company is 208 East 10<font style="font-size:8.5pt;"><sup style="font-size:85%; vertical-align:top">th</sup></font>&#160;Street, Austin, Texas 78701.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>Beneficial ownership includes  shares of common stock and shares of common stock issuable upon exercise of a warrant that are subject to a 4.99% ownership blocker, pursuant to which shares of our common stock may not be issued to the extent such issuance would cause Sabby Volatility Warrant Master Fund, Ltd. to beneficially </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own more than 4.99% of our outstanding common stock</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;The share ownership numbers and percentages for Sabby Volatility Warrant Master Fund, Ltd. in the table above reflect this 4.99% </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">blocker. As of August 1, 2018, Sabby Volatility Warrant Master Fund, Ltd. holds a warrant to purchase 1,141,870 shares of our common stock and has the right to acquire from us 350,000 shares of our common stock.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Sabby Management, LLC is the investment mana</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ger of Sabby Volatility Warrant Master Fund, Ltd. and shares voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of Sabby Volatility War</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rant Master Fund, Ltd. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The address of principal business office of Sabby Volatility Warrant Mast</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er Fund, Ltd., Sabby Management, LLC and Hal Mintz is 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458. Sabby Volatility Warrant Master Fund, Ltd. is not a registered broker-dealer or an affiliate of a registered broker-dealer.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Beneficial ownership includes  shares of common stock issuable upon exercise of a warrant that are subject to a 9.99% ownership blocker, pursuant to which shares of our common stock may not be issued to the extent such issuance would cause Hudson Bay Master Fund, Ltd. to beneficially own more than 9.99% of our outstanding common stock. The share ownership numbers and percentages in the table above reflect this 9.99% blocker. As of August 1, 2018, Hudson Bay Master Fund, Ltd. holds a warrant to purchase 1,141,870 shares of our common stock. Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Sander Gerber disclaims beneficial ownership over these securities.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes (a) 1,614,152 shares of common stock held by Laura Lane Biosciences, LLC and (b) 645,572 shares of common stock that Mr.&#160;Varner has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options. Mr.&#160;Varner holds voting power over the shares held by Laura Lane Biosciences, LLC.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 78,008 shares of common stock that Dr.&#160;Pham has the right to acquire from us within 60 days of Aguste 1, 2018 pursuant to the exercise of stock options.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 492,521 shares of common stock that Mr.&#160;Confer has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 307,111 shares of common stock that Mr.&#160;Friedman has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 307,111 shares of common stock that Mr.&#160;Pearson has the right to acquire from us within 60 days of August 1, 2018 pursuant to the exercise of stock options.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers for the year ended December&#160;31, 2017, which consist of our principal executive officer and our two other most highly compensated executive officers, are:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">J. Rodney Varner, our Chief Executive Officer;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.53%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Julien L. Pham, M.D., M.P.H., our President and Chief Operating Officer; and</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.53%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ryan M. Confer, our Chief Financial Officer.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:20pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary Compensation Table</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:69%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Principal Position</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary<font style="font-weight:normal;"><br /></font>($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock<font style="font-weight:normal;"><br /></font>Awards<font style="font-weight:normal;"><br /></font>($)(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All other<font style="font-weight:normal;"><br /></font>compensation<font style="font-weight:normal;"><br /></font>($)(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total<font style="font-weight:normal;"><br /></font>($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">J. Rodney Varner</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,000</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,069</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,069</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Julien L. Pham</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Operating Officer</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ryan M. Confer</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388,630</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,492</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">585,122</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock awards granted during 2017. These amounts have been computed in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are described in Note 5 to our financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2017.&#160;These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This column reflects medical and term life insurance premiums paid by us on behalf of each of the named executive officers. The insurance benefits are provided to the named executive officers on the same terms as provided to all of our regular full-time employees. For more information regarding these benefits, see below under &#8220;&#8212;Perquisites, Health, Welfare and Retirement Benefits.&#8221;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Salary</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The base salary of our named executive officers is generally determined and approved periodically or in connection with the commencement of employment of the executive, by our Board. As of December&#160;31, 2017, base salaries for our named executive officers, which became effective as of October&#160;1, 2016 for Mr.&#160;Varner and Mr.&#160;Confer, and as of October&#160;23, 2016 for Dr.&#160;Pham, are provided below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:68%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017&#160;Base<font style="font-weight:normal;"><br /></font>Salary<font style="font-weight:normal;"><br /></font>($)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">J. Rodney Varner</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,000</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Julien Pham</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Confer</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time our Board or Compensation Committee may approve bonuses for our named executive officers based on individual performance, company performance or as otherwise determined appropriate. In 2017, our executive officers were not entitled to any target or minimum bonus and no specific performance goals or bonus program were established for our named executive officers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Mr.&#160;Varner&#8217;s employment agreement, he is eligible to receive an annual cash bonus upon the achievement of performance objectives mutually agreed between Mr.&#160;Varner and the Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Dr. Pham&#8217;s amended and restated employment agreement, he is eligible to receive an annual cash bonus upon the achievement of performance objectives mutually agreed between Dr.&#160;Pham and the Board. The amount of the bonus for 2018 is up to 33.33% of Dr. Pham&#8217;s then-current base salary; the amount of the bonus after 2018 will be determined by the Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk515880113"></a>Pursuant to Mr.&#160;Confer&#8217;s employment agreement, he is eligible to receive an annual cash bonus upon the achievement of performance objectives mutually agreed between Mr.&#160;Confer and the Board.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity-Based Incentive Awards</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees and consultants, including our named executive officers. The Board is responsible for approving equity grants. Stock awards in exchange for services were the only form of equity awards we granted to our named executive officers in 2017.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically used stock options as an incentive for long-term compensation to our named executive officers because they are able to profit from stock options only if our stock price increases relative to the stock option&#8217;s exercise price, which exercise price is set at no less than the fair market value of our common stock on the date of grant. We may grant equity awards at such times as our Board determines appropriate. Our executives generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment with us. Additional grants may be made periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the initial public offering of our common stock, we granted all stock options pursuant to our 2009 Equity Incentive Plan. Following our initial public offering, we will grant equity incentive awards under the terms of our 2018 Equity Incentive Plan.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#8220;&#8212;Outstanding Equity Awards at Fiscal&#160;Year-End.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk515985748"></a>In May 2017, the Board granted an award of 73,526 shares of common stock to Mr.&#160;Confer in consideration of past services. Each of these shares had a value of $5.29 per share and was fully vested on the date of grant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Named Executive Officers</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Employment Agreement with Rodney Varner</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into an employment agreement with Mr.&#160;Varner, our Chief Executive Officer, which became effective in April 2018, following the closing of the initial public offering of our common stock. Mr.&#160;Varner&#8217;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the agreement, Mr.&#160;Varner is initially entitled to receive an annual base salary of $350,000. The agreement provides that the Company may pay Mr.&#160;Varner a bonus as described above under &#8220;&#8212;Bonus Compensation&#8221; and provides that the Company may grant to Mr.&#160;Varner options to purchase shares of common stock.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement provides that during the term of Mr.&#160;Varner&#8217;s employment with us and for one year after the termination of his employment, Mr.&#160;Varner will not encourage any of our employees or consultants to leave Genprex and will not compete or assist others to compete with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, prior to a change of control, we terminate Mr.&#160;Varner&#8217;s employment without cause or if Mr.&#160;Varner resigns for good reason, and Mr.&#160;Varner delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Mr.&#160;Varner: (i)&#160;a severance payment equal to 18 months of Mr.&#160;Varner&#8217;s base salary then in effect; (ii)&#160;a payment equal to Mr.&#160;Varner&#8217;s then applicable annual target bonus, calculated at full attainment; (iii)&#160;reimbursement of COBRA premium payments made by Mr.&#160;Varner for the 12 months following such termination; and (iv)&#160;acceleration as to 100% of Mr.&#160;Varner&#8217;s unvested equity awards from us, subject in the case of (i)&#160;and (ii) to our having at least $5&#160;million in cash or cash equivalents and a net worth of at least $5&#160;million on the date of termination.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, within 12 months following a chang</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e of control, Mr.&#160;Varner&#8217;s employment is terminated without cause or Mr.&#160;Varner resigns for good reason, and he delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Mr.&#160;Varner: (i)&#160;a severance payment equal to</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 18 months of Mr.&#160;Varner&#8217;s base salary then in effect; (ii)&#160;a payment equal to Mr.&#160;Varner&#8217;s then applicable target bonus for 18 months, calculated at full attainment; (iii)&#160;reimbursement of COBRA premium payments made by Mr.&#160;Varner for the 18 months follow</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing such termination; and (iv)&#160;acceleration as to 100% of Mr.&#160;Varner&#8217;s unvested equity awards from us, subject in the case of (i)&#160;and (ii) to our having at least $5&#160;million in cash or cash equivalents and a net worth of at least $5&#160;million on the date of t</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ermination.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of Mr.&#160;Varner&#8217;s employment agreement, &#8220;cause&#8221; means the occurrence of any of the following events: (i)&#160;a determination by our Board that Mr.&#160;Varner&#8217;s performance is unsatisfactory after there has been delivered to him a written demand for performance which describes the specific deficiencies in his performance and the specific manner in which his performance must be improved, and which provides 30 business days from the date of notice to remedy such performance deficiencies; (ii)&#160;Mr.&#160;Varner&#8217;s conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude which our Board reasonably finds has had or will have a detrimental effect on our reputation or business; (iii)&#160;Mr.&#160;Varner&#8217;s engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and duties that materially harms us; (iv)&#160;Mr.&#160;Varner&#8217;s committing an act of fraud against, material misconduct or willful misappropriation of property belonging to us; or (v)&#160;Mr.&#160;Varner&#8217;s material breach of his confidentiality, invention assignment and noncompetition agreement with us or of any other unauthorized misuse of our trade secrets or proprietary information.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of Mr.&#160;Varner&#8217;s employment agreement, &#8220;good reason&#8221; means the occurrence of any of the following taken without Mr.&#160;Varner&#8217;s written consent and conditioned on (a)&#160;his providing us with notice of the basis for such resignation for good reason, (b)&#160;our failure to cure the event constituting good reason within 30 days after notice and (c)&#160;his termination of his employment within 30 days following the expiration of the cure period: (i)&#160;a material change in Mr.&#160;Varner&#8217;s position, titles, offices or duties; (ii)&#160;an assignment of any significant duties to Mr.&#160;Varner that are inconsistent with his positions or offices held under his employment agreement; (iii)&#160;a decrease in Mr.&#160;Varner&#8217;s then current annual base salary by more than 10% (other than in connection with a general decrease in the salary of all of our other similarly situated employees); or (iv)&#160;the relocation of Mr.&#160;Varner to a facility or a location more than 50 miles from his then current location.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amended and Restated Employment Agreement with Julien L. Pham, MD, MPH</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk511399132"></a>On May 23, 2018, we entered into an amended and restated employment agreement with Julien L. Pham, MD, MPH, our President and Chief Operating Officer. This employment agreement amended and restated the employment agreement we had entered into with Dr. Pham in October 2016.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk515880102"></a><a name="_Hlk515361327"></a>Dr. Pham&#8217;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the agreement, Dr. Pham is initially entitled to receive an annual base salary of $325,000. Dr. Pham is also entitl<a name="_Hlk515361327"></a>ed to receive a bonus&#160;upon the achievement of performance objectives agreed upon between our Board and Dr. Pham. The amount of the bonus for 2018 is up to 33.33% of Dr. Pham&#8217;s then-current base salary; the amount of the bonus after 2018 will be determined by our Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 23, 2018, we granted Dr. Pham options to purchase an aggregate of 659,346 shares of our common stock, at an exercise price of $9.80 per share. One-half of the options (the &#8220;Time Based Options&#8221;) vest based on Dr. Pham&#8217;s continued employment, with one-third of these options vesting on May 23, 2019, and the remaining two-thirds vesting in equal quarterly installments over the following two years.&#160; The other one-half of the options vest based on achievement, within time periods specified by our Board, of performance goals specified by our Board.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement provides that during the term of Dr. Pham&#8217;s employment with us and for one year after the termination of his employment, Dr. Pham will not encourage any of our employees or consultants </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to leave Genprex and will not compete or assist others to compete with us.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, prior to a change of control, we terminate Dr. Pham&#8217;s employment without cause or if Dr. Pham resigns for good reason, and Dr. Pham delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Dr. Pham: (i) a severance payment equal to 12 months of Dr. Pham&#8217;s base salary then in effect; (ii) a payment equal to Dr. Pham&#8217;s then applicable annual target bonus, calculated at full attainment; (iii) reimbursement of COBRA premium payments made by Dr. Pham for the 12 months following such termination; and (iv) acceleration as to 100% of Dr. Pham&#8217;s Time Based Options, subject in the case of (i) and (ii) to our having at least $5 million in cash or cash equivalents and a net worth of at least $5 million on the date of termination.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, within 12 months following a change of control, Dr. Pham&#8217;s employment is terminated without cause or Dr. Pham resigns for good reason, and he delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Dr. Pham: (i) a severance payment equal to 12 months of Dr. Pham&#8217;s base salary then in effect; (ii) a payment equal to Dr. Pham&#8217;s then applicable annual target bonus, calculated at full attainment; (iii) reimbursement of COBRA premium payments made by Dr. Pham for the 12 months following such termination; and (iv) acceleration as to 100% of Dr. Pham&#8217;s unvested equity awards from us, subject in the case of (i) and (ii) to our having at least $5 million in cash or cash equivalents and a net worth of at least $5 million on the date of termination.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of Dr. Pham&#8217;s employment agreement, &#8220;cause&#8221; means the occurrence of any of the following events: (i) a determination by our Board that Dr. Pham&#8217;s performance is unsatisfactory after there has been delivered to him a written demand for performance which describes the specific deficiencies in his performance and the specific manner in which his performance must be improved, and which provides 30 business days from the date of notice to remedy such performance deficiencies; (ii) Dr. Pham&#8217;s conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude which our Board reasonably finds has had or will have a detrimental effect on our reputation or business; (iii) Dr. Pham&#8217;s engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and duties that materially harms us; (iv) Dr. Pham&#8217;s committing an act of fraud against, material misconduct or willful misappropriation of property belonging to us; or (v) Dr. Pham&#8217;s material breach of his confidentiality, invention assignment and noncompetition agreement with us or of any other unauthorized misuse of our trade secrets or proprietary information. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of Dr. Pham&#8217;s employment agreement, &#8220;good reason&#8221; means the occurrence of any of the following taken without Dr. Pham&#8217;s written consent and conditioned on (a) his providing us with notice of the basis for such resignation for good reason, (b) our failure to cure the event constituting good reason within 30 days after notice and (c) his termination of his employment within 30 days following the expiration of the cure period: (i) a material change in Dr. Pham&#8217;s position, titles, offices or duties other than as provided in the agreement; (ii) an assignment of any significant duties to Dr. Pham that are inconsistent with his positions or offices held under his employment agreement; (iii) a decrease in Dr. Pham&#8217;s then current annual base salary (other than in connection with a general decrease in the salary of all of our other similarly situated employees); or (iv) the requirement that Dr. Pham relocate his personal residence to a location more than 50 miles from his then current residence.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Employment Agreement with Ryan Confer</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>We have entered into an employment agreement with Mr.&#160;Confer, our Chief Financial Officer, which became effective in April 2018, following the closing of the initial public offering of our common stock. Mr.&#160;Confer&#8217;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the agreement, Mr.&#160;Confer is initially entitled to receive an annual base salary of $240,000. The agreement provides that the Company may pay Mr.&#160;Confer a bonus as described above under &#8220;&#8212;Bonus </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation&#8221; and provides that the Company may grant to Mr.&#160;Confer options to purchase shares of common stock.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement provides that during the term of Mr.&#160;Confer&#8217;s employment with us and for one year after the termination of his employment, Mr.&#160;Confer will not encourage any of our employees or consultants to leave Genprex and will not compete or assist others to compete with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we terminate Mr.&#160;Confer&#8217; employment without cause or if Mr.&#160;Confer resigns for good reason, and Mr.&#160;Confer delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Mr.&#160;Confer: (i)&#160;a severance payment equal to 12 months of Mr.&#160;Confer&#8217; base salary then in effect; (ii)&#160;a payment equal to Mr.&#160;Confer&#8217;s then applicable annual target bonus, calculated at full attainment; (iii)&#160;reimbursement of COBRA premium payments made by Mr.&#160;Confer for the 12 months following such termination; and (iv)&#160;acceleration as to 100% of Mr.&#160;Confer&#8217;s unvested equity awards from us, subject in the case of (i)&#160;and (ii) to our having at least $5&#160;million in cash or cash equivalents and a net worth of at least $5&#160;million on the date of termination.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of Mr.&#160;Confer&#8217;s employment agreement, &#8220;cause&#8221; means the occurrence of any of the following events: (i)&#160;a determination by our Board that Mr.&#160;Confer&#8217;s performance is unsatisfactory after there has been delivered to him a written demand for performance which describes the specific deficiencies in his performance and the specific manner in which his performance must be improved, and which provides 30 business days from the date of notice to remedy such performance deficiencies; (ii)&#160;Mr.&#160;Confer&#8217;s conviction of or plea of nolo contendere to a felony or a crime involving moral turpitude which our Board reasonably finds has had or will have a detrimental effect on our reputation or business; (iii)&#160;Mr.&#160;Confer&#8217;s engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and duties that materially harms us; (iv)&#160;Mr.&#160;Confer&#8217;s committing an act of fraud against, material misconduct or willful misappropriation of property belonging to us; or (v)&#160;Mr.&#160;Confer&#8217;s material breach of his confidentiality, invention assignment and noncompetition agreement with us or of any other unauthorized misuse of our trade secrets or proprietary information.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of Mr.&#160;Confer&#8217;s employment agreement, &#8220;good reason&#8221; means the occurrence of any of the following taken without Mr.&#160;Confer&#8217;s written consent and conditioned on (a)&#160;his providing us with notice of the basis for such resignation for good reason, (b)&#160;our failure to cure the event constituting good reason within 30 days after notice and (c)&#160;his termination of his employment within 30 days following the expiration of the cure period: (i)&#160;a material change in Mr.&#160;Confer&#8217;s position, titles, offices or duties; (ii)&#160;an assignment of any significant duties to Mr.&#160;Confer that are inconsistent with his positions or offices held under his employment agreement; (iii)&#160;a decrease in Mr.&#160;Confer&#8217;s then current annual base salary by more than 10% (other than in connection with a general decrease in the salary of all of our other similarly situated employees); or (iv)&#160;the relocation of Mr.&#160;Confer to a facility or a location more than 50 miles from his then current location.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further described below under &#8220;&#8212;Potential Payments and Benefits upon Termination or Change in Control.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential Payments and Benefits upon Termination or Change in Control</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regardless of the manner in which a named executive officer&#8217;s service terminates, each named executive officer is entitled to receive amounts earned during his term of service, including unpaid salary. In addition, each Mr.&#160;Varner, Dr.&#160;Pham and Mr.&#160;Confer is entitled to receive certain benefits upon our termination of his employment without cause or his resignation for good reason, and Mr.&#160;Varner is entitled to receive certain additional benefits upon such a termination or resignation within 12 months after a change of control, all as provided above under &#8220;&#8212;Agreements with Named Executive Officers.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our named executive officers holds stock options that were granted subject to the genera</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l terms and termination and change in control provisions of our 2009 Equity Incentive Plan</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and, beginning in April 2018, our 2018 Equity Incentive Plan</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. A description of the termination and change in control provisions in our 2009 Plan </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 2018 Plan </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and ap</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plicable to the stock options granted to our named executive officers is provided below under &#8220;&#8212;Equity Benefit Plans&#8221; and &#8220;&#8212;Outstanding Equity Awards at Fiscal&#160;Year-End&#8221;&#160;and above under &#8220;&#8212;Equity-Based Incentive Awards.&#8221;</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Equity Awards at Fiscal&#160;Year-End</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth certain information regarding equity awards granted to our named executive officers that were outstanding as of December&#160;31, 2017.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="22" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards(1)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of<font style="font-weight:normal;"><br /></font>securities<font style="font-weight:normal;"><br /></font>underlying<font style="font-weight:normal;"><br /></font>unexercised<font style="font-weight:normal;"><br /></font>option (#)<font style="font-weight:normal;"><br /></font>exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of<font style="font-weight:normal;"><br /></font>securities<font style="font-weight:normal;"><br /></font>underlying<font style="font-weight:normal;"><br /></font>unexercised<font style="font-weight:normal;"><br /></font>option (#)<font style="font-weight:normal;"><br /></font>unexercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option<font style="font-weight:normal;"><br /></font>exercise<font style="font-weight:normal;"><br /></font>price<font style="font-weight:normal;"><br /></font>($)(2)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option<font style="font-weight:normal;"><br /></font>expiration<font style="font-weight:normal;"><br /></font>date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">J. Rodney Varner</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2016</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645,572</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2026</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Julien Pham</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,317</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Confer</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/25/2012</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,973</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.01</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7/25/2022</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161,396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.96</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/11/2026</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2016</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,894</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.29</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/3/2026</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="letter-spacing:-0.1pt;">All of the outstanding stock option awards were granted under and subject to the terms of our 2009 Equity Incentive Plan. As of December&#160;31, 2017, each option award becomes exercisable as it becomes vested and all vesting is subject to the executive&#8217;s continuous service with us through the vesting dates and the potential vesting acceleration described above under &#8220;&#8212;Potential Payments and Benefits upon Termination or Change in Control.&#8221;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All of the stock option awards were granted with a per share exercise price no less than the fair market value of one share of our common stock on the date of grant, as determined in good faith by our Board.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">3,392 shares will vest each month until October&#160;25, 2020.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Repricings</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not engage in any repricings or other modifications or cancellations of any of our named executive officers&#8217; outstanding equity awards during the fiscal year ended December 31, 2017.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Perquisites, Health, Welfare and Retirement Benefits</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. We do not provide a 401(k) plan to our employees at this time.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the premiums for medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nonqualified Deferred Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:10.46%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our Board may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E</font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">quity Benefit Plans</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Equity Incentive Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Equity Incentive Plan became effective upon the closing of the initial public offering of our common stock. After such date, no further grants will be made under the 2009 Plan.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Awards<font style="font-style:normal;">. The 2018 Plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance based stock awards, and other forms of equity compensation, which we refer to collectively as stock awards. Additionally, the 2018 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to&#160;non-employee&#160;directors and consultants of us and our affiliates.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve<font style="font-style:normal;">. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2018 Plan is 6,788,749 shares, which is the sum of (1) 3,605,037 new shares, plus (2)&#160;554,963 shares reserved for issuance under our 2009 Plan at the time our 2018 Plan became effective, plus (3)&#160;up to 2,628,749 shares subject to outstanding stock options or other stock awards that would have otherwise returned to our 2009 Plan (such as upon the expiration or termination of a stock award prior to vesting). Additionally, the number of shares of our common stock reserved for issuance under our 2018 Plan will automatically increase on January&#160;1 of each year, beginning on January&#160;1, 2019 and continuing through and including January&#160;1, 2028, by 5% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by our Board. The maximum number of shares that may be issued upon the exercise of ISOs under our 2018 Plan is 8,320,000 shares.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No person may be granted stock awards covering more than 1,040,000 shares of our common stock under our 2018 Plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value on the date the stock award is granted. Additionally, no person may be granted in a calendar year a performance stock award covering more than 2,080,000 shares or a performance cash award having a maximum value in excess of $2,000,000. Such limitations are designed to help assure that any deductions to which we would otherwise be entitled with respect to such awards will not be subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to any covered executive officer imposed by Section&#160;162(m) of the Code. In addition, the maximum number of shares of our common stock subject to stock awards granted under the 2018 Plan during any one calendar year to any&#160;non-employee&#160;director will not exceed $1,000,000 in total value, or, with respect to the calendar year in which a&#160;non-employee&#160;director is first appointed or elected to our Board, $2,000,000.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a stock award granted under the 2018 Plan expires or otherwise terminates for any reason prior to exercise or settlement, the shares of our common stock not acquired pursuant to the stock award again will become available for subsequent issuance under the 2018 Plan. In addition, the following types of shares under the 2018 Plan may become available for the grant of new stock awards under the 2018 Plan: (1)&#160;shares that are forfeited to or repurchased by us prior to becoming fully vested; (2)&#160;shares withheld to satisfy income or employment withholding taxes; or (3)&#160;shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2018 Plan may be previously unissued shares or reacquired shares bought by us on the open market. As of the date hereof, no awards have been granted and no shares of our common stock have been issued under the 2018 Plan.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<font style="font-style:normal;">. Our Board, or a duly authorized committee thereof, has the authority to administer the 2018 Plan. Our Board may also delegate to one or more of our officers the authority to (1)&#160;designate employees (other than officers) to be recipients of certain stock awards, and (2)&#160;determine the number of shares of common stock to be subject to such stock awards. Subject to the terms of the 2018 Plan, our Board or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan administrator has the authority to modify outstanding awards under our 2018 Plan. Subject to the terms of our 2018 Plan, the plan administrator has the authority to reduce the exercise, purchase or strike price of any outstanding stock award, cancel a</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<font style="font-style:normal;">. ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2018 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2018 Plan vest at the rate specified by the plan administrator.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the term of stock options granted under the 2018 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, all options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1)&#160;cash, check, bank draft or money order, (2)&#160;a broker-assisted cashless exercise, (3)&#160;the tender of shares of our common stock previously owned by the optionholder, (4)&#160;a net exercise of the option if it is an NSO, and (5)&#160;other legal consideration approved by the plan administrator.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#8217;s death.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on Incentive Stock Options<font style="font-style:normal;">. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans and the stock plans of any of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&#160;the term of the ISO does not exceed five years from the date of grant.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards<font style="font-style:normal;">. Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. Restricted stock awards may be granted in consideration for (1)&#160;cash, check, bank draft or money order, (2)&#160;services rendered to us or our affiliates, or (3)&#160;any other form of legal consideration. Common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock that has not vested will be forfeited or repurchased by us upon the participant&#8217;s cessation of continuous service for any reason.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>Restricted Stock Unit Awards<font style="font-style:normal;">. Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">award agreement, restricted stock units that have not vested wil</font><font style="font-style:normal;">l be forfeited upon the participant&#8217;s cessation of continuous service for any reason.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights<font style="font-style:normal;">. Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (1)&#160;the excess of the per share fair market value of our common stock on the date of exercise over the strike price, multiplied by (2)&#160;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2018 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the term of stock appreciation rights granted under the 2018 Plan, up to a maximum of 10 years. Unless the terms of a participant&#8217;s stock appreciation right agreement provides otherwise, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Awards<font style="font-style:normal;">. The 2018 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section&#160;162(m) of the Code. To help assure that the compensation attributable to performance-based awards will so qualify, our Compensation Committee can structure such awards so that stock or cash will be issued or paid pursuant to such award only after the achievement of certain&#160;pre-established&#160;performance goals during a designated performance period.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>The performance goals that may be selected include one or more of the following: (1)&#160;earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3)&#160;earnings before interest, taxes, depreciation and amortization; (4)&#160;earnings before interest, taxes, depreciation, amortization and legal settlements; (5)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (6) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation; (7)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue; (8)&#160;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation, other&#160;non-cash&#160;expenses and changes in deferred revenue; (9)&#160;total stockholder return; (10)&#160;return on equity or average stockholder&#8217;s equity; (11)&#160;return on assets, investment, or capital employed; (12)&#160;stock price; (13)&#160;margin (including gross margin); (14) income (before or after taxes); (15) operating income; (16)&#160;operating income after taxes;&#160;(17)&#160;pre-tax&#160;profit; (18)&#160;operating cash flow; (19)&#160;sales or revenue targets; (20)&#160;increases in revenue or product revenue; (21)&#160;expenses and cost reduction goals; (22)&#160;improvement in or attainment of working capital levels; (23)&#160;economic value added (or an equivalent metric); (24) market share; (25)&#160;cash flow; (26)&#160;cash flow per share; (27)&#160;cash balance; (28)&#160;cash burn; (29)&#160;cash collections; (30)&#160;share price performance; (31)&#160;debt reduction; (32)&#160;implementation or completion of projects or processes (including, without limitation, discovery of a preclinical drug candidate, recommendation of a drug candidate to enter a clinical trial, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions (such as IND, BLA and NDA), regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, and product supply); (33) stockholders&#8217; equity; (34)&#160;capital expenditures; (35)&#160;financings; (36) operating profit or net operating profit; (37)&#160;workforce diversity; (38)&#160;growth of net income or operating income; (39)&#160;employee retention; (40)&#160;initiation of studies by specific dates; (41)&#160;budget management; (42)&#160;submission to, or approval by, a regulatory body (including, but not limited to the FDA) of an applicable filing or a product; (43)&#160;regulatory milestones; (44)&#160;progress of internal research or development programs; (45)&#160;progress of partnered programs; (46)&#160;partner satisfaction; (47)&#160;timely </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completion of clinical trials; (48)&#160;milestones related to research development (including, but not limited to, preclinical </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and clinical studies), product development and manufacturing; (49)&#160;expansion of sales in additional geographies or markets; (50)&#160;research progress, including the development of programs; (51)&#160;strategic partnerships or transactions (including&#160;in-licensing&#160;a</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd&#160;out-licensing&#160;of intellectual property; (52)&#160;filing of patent applications and granting of patents; and (53)&#160;and to the extent that an award is not intended to comply with Section&#160;162(m) of the Code, other measures of performance selected by our </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (1)&#160;in the award agreement at the time the award is granted or (2)&#160;in any other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (a)&#160;to exclude restructuring and/or other nonrecurring charges; (b)&#160;to exclude exchange rate effects; (c)&#160;to exclude the effects of changes to generally accepted accounting principles; (d)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (e)&#160;to exclude the effects of any &#8220;items of an unusual nature or of infrequency of occurrence or&#160;non-recurring&#160;items&#8221; as determined under generally accepted accounting principles; (f)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (g)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (h)&#160;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation,&#160;spin-off,&#160;combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (i)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (j)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (k)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; (l)&#160;to exclude the effect of any other unusual,&#160;non-recurring&#160;gain or loss or other extraordinary item; and (m)&#160;to exclude the effects of the timing of acceptance for review and/or approval of submissions to the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award to award.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Stock Awards<font style="font-style:normal;">. The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure<font style="font-style:normal;">. In the event that there is a specified type of change in our capital structure, such as a stock split or recapitalization, appropriate adjustments will be made to (1)&#160;the class and maximum number of shares reserved for issuance under the 2018 Plan, (2)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (3)&#160;the class and maximum number of shares that may be issued upon the exercise of ISOs, (4)&#160;the class and maximum number of shares subject to stock awards that can be granted to any person in a calendar year (as established under the 2018 Plan pursuant to Section&#160;162(m) of the Code), and (5)&#160;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions<font style="font-style:normal;">. In the event of certain specified significant corporate transactions (or a change in control, as described below), the plan administrator has the discretion to take any of the following actions with respect to stock awards:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">accelerate the vesting of the stock award and provide for its termination prior to the effective time of the transaction;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrange for the lapse of any reacquisition or repurchase right held by us;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as our Board may deem appropriate; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">make a payment equal to the excess of (a)&#160;the value of the property the participant would have received upon exercise of the stock award immediately prior to the effective time of the transaction, over (b)&#160;the exercise price otherwise payable by the participant in connection with such exercise.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2018 Plan, a corporate transaction is generally the consummation of (1)&#160;a sale or other disposition of all or substantially all of our assets, (2)&#160;a sale or other disposition of more than 50% of our outstanding securities, (3)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Control<font style="font-style:normal;">. In addition to the above, the plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change in control. Under the 2018 Plan, a change in control is generally (1)&#160;the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2)&#160;a consummated merger, consolidation or similar transaction immediately after which our stockholders cease to own more than 50% of the combined voting power of the surviving entity (or its parent); (3) a consummated sale, lease, exclusive license or other disposition of all or substantially of our assets; (4)&#160;a complete dissolution or liquidation of the Company, except for a liquidation into a parent corporation; or (5)&#160;when a majority of our Board becomes comprised of individuals who were not serving on our Board on the date of adoption of the 2018 Plan, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board then still in office.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment and Termination<font style="font-style:normal;">. Our Board has the authority to amend, suspend, or terminate our 2018 Plan, provided that such action does not impair the existing rights of any participant without such participant&#8217;s written consent. No ISOs may be granted after the 10th anniversary of the date our Board adopted our 2018 Plan.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:7.69%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2009 Equity Incentive Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board and our stockholders approved our 2009 Equity Incentive Plan in November 2009. The 2009 Plan was subsequently amended by our Board and stockholders, most recently in August 2012. As of February&#160;28, 2018, there were 554,963 shares remaining available for the grant of stock awards under our 2009 Plan and there were outstanding stock options covering a total of 2,628,749 shares that were granted under our 2009 Plan.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No additional awards will be granted under the 2009 Plan, and all outstanding awards granted under the 2009 Plan that are repurchased, forfeited, expire or are canceled will become available for grant under the 2018 Plan in accordance with its terms.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock awards<font style="font-style:normal;">. The 2009 Plan provides for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards, or collectively, stock awards. With the exception of ISOs, all stock awards may be granted to employees, including officers, and to our&#160;non-employee&#160;directors and consultants and those of our affiliates. ISOs may be granted only to employees. We have only granted stock options under the 2009 Plan.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve<font style="font-style:normal;">. The aggregate number of shares of our common stock reserved for issuance pursuant to awards under the 2009 Plan is 2,628,749.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>If a stock award granted under the 2009 Plan is forfeited to us or repurchased by us because of the failure to meet a contingency or condition required for vesting, such shares will become available for subsequent issuance </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the 2018 Plan. In addition, shares withheld to satisfy inc</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ome or employment withholding taxes and shares used to pay the exercise price of a stock option will become available for the grant of new stock awards under the 2018 Plan. Shares issued under the 2009 Plan may be authorized but unissued or reacquired comm</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on stock.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<font style="font-style:normal;">. Our Board, or a duly authorized committee thereof, has the authority to administer the 2009 Plan. Subject to the terms of the 2009 Plan, our Board or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator has the authority to modify outstanding awards under our 2009 Plan. Subject to the terms of our 2009 Plan, the plan administrator has the authority to reduce the exercise price of any outstanding stock option, cancel any outstanding stock option in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<font style="font-style:normal;">. ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2009 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2009 Plan vest at the rate specified by the plan administrator.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the term of stock options granted under the 2009 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionholder may generally exercise any vested options for a period of three months following the cessation of service, with respect to employee optionholders. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In no event may an option be exercised beyond the expiration of its term.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be as determined by the plan administrator.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the plan administrator provides otherwise, options generally are not transferable except by will or by the laws of descent and distribution.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on Incentive Stock Options<font style="font-style:normal;">. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&#160;the option is not exercisable after the expiration of five years from the date of grant.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure<font style="font-style:normal;">. In the event that there is a specified type of change in our capital structure, such as a stock split or recapitalization, appropriate adjustments will be made to (a)&#160;the class and maximum number of shares reserved for issuance under the 2009 Plan, (b)&#160;the class and maximum number of shares that may be issued upon the exercise of ISOs, and (c)&#160;the class and number of shares and price per share of stock subject to all outstanding stock awards.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions</font><font style="font-style:normal;">. In the event of a change in control, un</font><font style="font-style:normal;">less otherwise provided in a stock award or other written agreement between us and the holder of a stock award, each stock award will be treated as the plan administrator determines, arranging for the assumption or substitution of a stock award by a succes</font><font style="font-style:normal;">sor entity. If the successor entity does not assume or substitute for the stock award, the vesting and exercisability, if applicable, of the stock award will accelerate in full.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our plan administrator is not obligated to treat all stock awards or portions thereof or all holders of stock awards, even those that are of the same type, in the same manner.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2009 Plan, a change in control is generally the occurrence of (1)&#160;any transaction or series of related transactions in which in excess of 50% of our voting power is transferred; (2)&#160;the replacement of a majority of the members of our Board during any&#160;12-month&#160;period by directors whose appointment or election is not endorsed by a majority of the members of our Board prior to the date of such appointment or election; or (3)&#160;the acquisition by a third party of our assets that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of our assets immediately prior to such acquisition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Control<font style="font-style:normal;">. The plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change in control.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment and Termination<font style="font-style:normal;">. Our Board has the authority to amend, alter, suspend, or terminate our 2009 Plan, provided that such action does not impair the existing rights of any participant without such participant&#8217;s written consent.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:7.69%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2018 Employee Stock Purchase Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Employee Stock Purchase Plan, or ESPP, will become effective when the Board determines to make this benefit available to employees. The purpose of the ESPP is to retain the services of new employees and secure the services of new and existing employees while providing incentives for such individuals to exert maximum efforts toward our success and that of our affiliates.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve<font style="font-style:normal;">. The ESPP authorizes the issuance of 208,050 shares of our common stock pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January&#160;1 of each calendar year, beginning on January&#160;1, 2019 and continuing through and including January&#160;1, 2028 by 2% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by our Board. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code. As of the date hereof, no shares of our common stock have been purchased under the ESPP.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration<font style="font-style:normal;">. Our Board has delegated its authority to administer the ESPP to our Compensation Committee. The ESPP is implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payroll Deductions<font style="font-style:normal;">. Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of our common stock under the ESPP. Unless otherwise determined by our Board, common stock will be purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value of a share of our common stock on the first date of an offering or (b) 85% of the fair market value of a share of our common stock on the date of purchase.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>Limitations<font style="font-style:normal;">. Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by our Board: (a)&#160;customarily employed for more than 20 hours per week, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">(b)&#160;customarily employed for more than five months per calendar year or (c)&#160;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may pur</font><font style="font-style:normal;">chase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will </font><font style="font-style:normal;">be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to Section&#160;424(d) of the Code.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure<font style="font-style:normal;">. In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or similar transaction, the Board will make appropriate adjustments to (a)&#160;the class and number of shares reserved under the ESPP, (b)&#160;the class and maximum number of shares by which the share reserve may increase automatically each year, (c)&#160;the class and number of shares and purchase price of all outstanding offerings and purchase rights and (d)&#160;the class and number of shares that are the subject of the purchase limits under each ongoing offering.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions<font style="font-style:normal;">. In the event of certain significant corporate transactions, including the consummation of: (1)&#160;a sale or other disposition of all or substantially all of our assets, (2)&#160;the sale or other disposition of more than 50% of our outstanding securities, (3)&#160;a merger, consolidation or similar transaction where we do not survive the transaction, and (4)&#160;a merger, consolidation or similar transaction where we do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days prior to such corporate transaction, and such purchase rights will terminate immediately after such purchase.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Amendments, Termination<font style="font-style:normal;">. Our Board has the authority to amend or terminate our ESPP, provided that, except in certain circumstances, any such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, we have not paid cash compensation to any of our&#160;non-employee&#160;directors for service on our Board. As set forth below, we did pay equity compensation to our&#160;non-employee&#160;directors in 2016 for service on our Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reimbursed and will continue to reimburse all of our&#160;non-employee&#160;directors for their travel, lodging and other reasonable expenses incurred in attending meetings of our Board and committees of our Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, the aggregate number of shares outstanding under all options to purchase our common stock held by our&#160;non-employee&#160;directors were: Mr.&#160;Friedman: 307,111; and Mr.&#160;Pearson: 307,111.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Board adopted a new compensation policy in September 2017 that was amended in April 2018 and became effective upon the completion of the initial public offering of our common stock and will be applicable to all of our&#160;non-employee&#160;directors. This compensation policy provides that each such&#160;non-employee&#160;director may receive any of the following compensation elements for service on our Board:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an annual cash retainer of $25,000;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.32%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>for each&#160;non-employee&#160;director who first joins our Board, an initial option grant to purchase shares of our common stock with a value of $175,000, prorated monthly for the period between the date of our last annual meeting of stockholders and the date such&#160;non-employee&#160;director first joins our Board, on </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the date of commencement of service on the board, vesting on the earlier of the&#160;one-year&#160;anniversary of the grant date or the day prior to the next annual meeting of stockholders; and</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.32%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">an annual option grant to purchase shares of our common stock having a value of $175,000 for each&#160;non-employee&#160;director serving on the Board on the date of our annual stockholder meeting, vesting one year following the grant date.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the option grants described above will vest and become exercisable subject to the director&#8217;s continuous service to us, provided that each option will vest in full upon a change in control (as defined under our 2018 Plan). The term of each option will be 10 years, subject to earlier termination as provided in the 2018 Plan. The options will be granted under our 2018 Plan, the terms of which are described in more detail above under &#8220;&#8212;Equity Benefit Plans&#8212;2018 Equity Incentive Plan.&#8221;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:20pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELATED PARTY TRANSACTIONS</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following includes a summary of transactions since January&#160;1, 2015 to which we have been a party, in which the amount involved in the transaction exceeded 1% of the average of our total assets at December&#160;31, 2017 and 2016, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of any class of our voting securities or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Executive Officer and Director Compensation.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuances of Securities to Domecq Sebastian, LLC</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we issued an option to purchase 161,396 shares of our common stock with an exercise price of $0.96 per share, to Domecq Sebastian, LLC, the beneficial owner of more than 5% of a class of our voting securities which is affiliated with David Nance, a former director and officer who is now deceased, in exchange for services provided by that entity.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loan from Domecq Sebastian, LLC</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;8, 2017, we received a loan from Domecq Sebastian, LLC in the amount of $200,000 and executed a Promissory Note under which we agreed to repay the loan on or before March&#160;31, 2018, with interest at a rate of 15% per annum. The note carried a 18% default interest on amounts paid after the maturity date. We repaid this note in April 2018 with a portion of the proceeds of the initial public offering of our common stock.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase of Shares in Our Initial Public Offering by Christy Mallinson Nance</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christy Mallinson Nance, who holds voting and dispositive power over the securities held by Domecq Sebastian, LLC, purchased an aggregate of 50,000 shares of our common stock in our initial public offering.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuances of Securities to Jack A. Roth, MD, FACS</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a Consulting Agreement between us and Jack A. Roth, MD, FACS, the beneficial owner of more than 5% of a class of our voting securities and the Chairman of our SMA Board, we issue to Dr.&#160;Roth shares of our common stock each year. We issue these shares to Dr.&#160;Roth at the beginning of each calendar quarter. Under this arrangement, we issued to Dr.&#160;Roth an aggregate of 133,683 shares of our common stock in each of 2015, 2016 and 2017 and another 66,842 shares of our common stock in 2018.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase of Shares in Our Initial Public Offering by JREG Investments, Ltd.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JREG Investments, Ltd., an affiliate of Dr.&#160;Roth, purchased an aggregate of 40,000 shares of our common stock in our initial public offering.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuances of Securities to</font><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;Viet-An&#160;Hoan Ly</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From February 2015 to December&#160;31, 2017, we entered into a series of subscription agreements with various investment funds affiliated with&#160;Viet-An&#160;Hoan Ly, who is, together with his affiliated investment funds, a beneficial owner of more than 5% of a class of our voting securities, pursuant to which we issued and sold to such entities an aggregate of 687,621 shares of our common stock at a purchase price of $5.29 per share, and received gross proceeds of approximately $3.6&#160;million.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Warrants to Purchase Common Stock</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, an entity affiliated with Mr.&#160;Ly exercised a warrant that we had issued to a different entity in December 2013 and that had been transferred to the entity affiliated with Mr.&#160;Ly in December 2013. The warrant was exercisable for 66,841 shares of our common stock, with an exercise price of $2.59 per share, and was exercised in full in February 2016.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, we issued to Mr.&#160;Ly a warrant exercisable for an aggregate of 542,656 shares of our common stock, with an exercise price of $5.29 per share. The purchase price of the warrant was $8,119. That warrant is currently exercisable, expires on November&#160;1, 2026, and is currently outstanding.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, we issued (a) a warrant  to purchase 425,000 shares of common stock at an exercise price of $5.00 per share to Cancer Revolution, LLC, and (b) a warrant to purchase 144,352 shares of common stock at an exercise price of $5.00 per share to Inception Capital Management, LLC, each of which is an entity affiliated with Mr. Ly, in conjunction with past and future services provided to us. . These warrants are not exercisable before September 24, 2018.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;margin-left:8.55%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Options to Purchase Common Stock</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we granted to Mr.&#160;Ly an option to purchase 56,815 shares of our common stock, with an exercise price of $0.96 per share. This option was fully vested at the time of grant and is currently outstanding.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loan from Viet-An Hoan Ly</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;9, 2018, we received a loan from Viet Ly in the amount of $25,000 and executed a Promissory Note under which we agreed to repay the loan on or before June&#160;9, 2018, with no interest rate if paid prior to maturity and a rate of 10% per annum if not paid on maturity. We have repaid this note with a portion of the proceeds of the initial public offering of our common stock.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Services Provided by Confer Capital, Inc.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We paid $65,000 in 2016 to Confer Capital, Inc., an entity affiliated with Ryan Confer, our Chief Financial Officer. Confer Capital, Inc. provided strategic, financial, and executive managerial services to us at times when Ryan Confer was not our employee.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Payments to Introgen Research Institute, Inc.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to an Amended Collaboration and Assignment Agreement dated July&#160;1, 2011 between us and Introgen Research Institute, Inc., or IRI (the &#8220;2011 IRI Collaboration Agreement&#8221;), we are obligated to IRI a royalty of 1% of net sales of licensed products and 1% of certain other payments received by us, with respect to intellectual property owned by MD Anderson and licensed to us by IRI. This royalty obligation continues for 21 years after the later of the termination of the MD Anderson License Agreement and the termination of the Technology Sublicense Agreement. IRI is affiliated with Rodney Varner, our Chief Executive Officer and the Chairman of our Board. We made no payments under the 2011 IRI Collaboration Agreement in 2016 or 2017.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loan from Rodney Varner</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>On March&#160;28, 2018, we received a loan from Rodney Varner in the amount of $45,000 and executed a Promissory Note under which we agreed to repay the loan on or before April&#160;6, 2018, with no interest rate if paid </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to maturity and a rate of 10% per annum if not paid on maturity. We repaid this note prior to the maturity date with a portion of the proceeds from the initial publ</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ic offering of our common stock.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase of Shares in Our Initial Public Offering by Rodney Varner</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr.&#160;Varner purchased an aggregate of 10,000 shares of our common stock in our initial public offering.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employment and Consulting Arrangements</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a consulting agreement with Viet-An Hoan Ly, pursuant to which we agreed to pay Mr. Ly $175,000 per year, which amount may vary as determined by Mr. Ly and us, for strategic consulting services.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk515985604"></a>In May 2018, we entered into an amended and restated employment agreement with Julien Pham, our President and Chief Operating Officer. This agreement <a name="_Hlk515985604"></a>amended and restated an employment agreement we entered into with Dr. Pham in October 2016. The amended and restated employment agreement is described in the section titled &#8220;Executive Officer and Director Compensation.&#8221; </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into an employment agreement with each of Rodney Varner, our Chief Executive Officer and Ryan Confer, our Chief Financial Officer, each of which employment agreements became effective upon the closing of the initial public offering of our common stock. These agreements are described in the section titled &#8220;Executive Officer and Director Compensation.&#8221; </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to a Consulting Agreement dated November&#160;5, 2009, we pay to Jack A. Roth, MD, FACS, annual cash fees at the highest amount which is consistent with the policies of MD Anderson, increased annually by a percentage equal to the automatic cost of living adjustment set forth for Social Security. Under this arrangement, we paid Dr.&#160;Roth an aggregate of $185,826 in 2015, $192,191 in 2016 and $197,192 in 2017.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options Granted to Executive Officers and Directors</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted stock options and shares of our common stock to our executive officers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we granted Rodney Varner an option to purchase 645,572 shares of common stock and we granted to each of Ryan Confer, David Friedman and Robert Pearson an option to purchase 161,396 shares of common stock, each at an exercise price of $0.96 per share. Each option was fully vested on the date of grant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, we granted Julien Pham an option to purchase 162,800 shares of common stock, at an exercise price of $5.29 per share. The option vests at a rate of 1/48 of the shares subject to the option each month following October&#160;26, 2016.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk515889140"></a><a name="_Hlk515889140"></a>Also in November 2016, we granted Ryan Confer an option to purchase 86,894 shares of common stock, at an exercise price of $5.29 per share. Each option was fully vested on the date of grant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, we granted an award of 73,526 shares of common stock to Ryan Confer in consideration of past services. Each of these shares had a value of $5.29 per share and was fully vested on the date of grant.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, we granted Julien Pham an option to purchase 659,346 shares of common stock, at an exercise price of $9.80 per share. One-half of the options (the &#8220;Time Based Options&#8221;) vest based on Dr. Pham&#8217;s continued employment, with one-third of these options vesting on May 23, 2019, and the remaining two-thirds vesting in equal quarterly installments over the following two years.&#160; The other one-half of the options vest based on achievement, within time periods specified by our Board, of performance goals specified by our Board.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also in May 2018, we granted Ryan Confer an option to purchase 327,236 shares of common stock, at an exercise price of $9.80 per share. The options vest based on Mr. Confer&#8217;s continued employment, with one-third of these options vesting on May 23, 2018, and the remaining two-thirds vesting in equal quarterly installments over the following three years.&#160; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Transactions with Related Persons</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related-person transactions.&#8221; For purposes of our policy only, a &#8220;related-person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceeds the lesser of $120,000 and one percent of the average of our total assets for our last two completed fiscal years.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than five percent of our common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board) for review. The presentation must include a description of, among other things, all of the parties thereto, the direct and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management&#8217;s recommendation. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our Audit Committee or another independent body of our Board takes into account the relevant available facts and circumstances including, but not limited to:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the risks, costs and benefits to us;</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0.48%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms of the transaction;</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of other sources for comparable services or products; and</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the terms available to or from, as the case may be, unrelated third parties.</p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOUSEHOLDING OF PROXY MATERIALS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>If you and other residents at your mailing address own shares of the Company&#8217;s common stock through a broker or other nominee, you may have elected to receive only one copy of this proxy statement and the Company&#8217;s Annual Report. If you and other residents at your mailing address own shares of common stock in your own names, you may have received only one copy of this proxy statement and the Annual Report, unless you provided the Company&#8217;s transfer agent with contrary instructions. This practice, known as &#8220;householding,&#8221; is designed to reduce the Company&#8217;s printing and postage costs. You may promptly obtain an additional copy of this proxy statement, enclosed proxy card and our Annual Report by sending a written request to Genprex, Inc., attention Secretary, Dell Medical Center, Health Discovery Building, 1701 Trinity Street, Suite 3.322, Austin TX 78712 or by calling us at (512) 537-7997. If you hold your shares through a broker or other nominee and wish to discontinue householding or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to change your househol</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ding election, you may do so by contacting your broker</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If you hold shares in your own name and wish to discontinue householding or change your householding election, you may do so by </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contacting </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">V Stock Transfer, LLC, by telephone at (855) 9VSTOCK</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER MATTERS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Order of the Board of Directors,</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rodney Varner</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rodney Varner</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 29, 2018</p> <div></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><img src="gl3wrlsmluwf000002.jpg" title="" alt="" style="width:624px;height:482px;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EVENT # CLIENT # PROXY TABULATOR FOR Genprex, Inc. P.O. BOX 8016 CARY, NC 27512-9903 The undersigned hereby appoints Rodney Varner and Ryan Confer, and each of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes each of them to vote all the shares of capital stock of Genprex, Inc. that the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED FOR THE ELECTION OF THE DIRECTOR NOMINEE IN PROPOSAL 2 AND FOR PROPOSALS 1 AND 3.All votes must be received by 11:59 P.M., Eastern Time, September 30, 2018. MAIL OR &#8226; Mark, sign and date your Proxy Card/Voting Instruction Form. &#8226; Detach your Proxy Card/Voting Instruction Form. &#8226; Return your Proxy Card/Voting Instruction Form in the postage-paid envelope provided. OR Go To www.proxypush.com/GNPX &#8226; Cast your vote online. &#8226; View meeting documents. &#8226; Use any touch-tone telephone. &#8226; Have your Proxy Card/Voting Instruction Form ready. &#8226; Follow the simple recorded instructions. 866-356-9132 INTERNET TELEPHONE VOTE BY: Annual Meeting of Genprex, Inc. to be held on Monday, October 1, 2018 for Holders as of August 21, 2018 This proxy is being solicited on behalf of the Board of Directors Please separate carefully at the perforation and return just this portion in the envelope provided. 4: To conduct any other business properly brought before the meeting. 3: To ratify the selection by the Audit Committee of the Board of Directors of Daszkal Bolton LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018. Date: Monday, October 1, 2018 Time: 10:30 A.M. (Central Daylight Time) Place: W2O Group, 507 Calles Street, Suite 112, Austin, TX 78702 See Voting Instruction on Reverse Side. ANNUAL MEETING OF GENPREX, INC. Please Sign Here Please Date Above Please Sign Here Please Date Above Please sign exactly as your name(s) appears on your stock certificate. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the proxy. Authorized Signatures - This section must be completed for your Instructions to be executed. To attend the meeting and vote your shares in person, please mark this box. For For For For Against Abstain For Against Abstain Directors Recommend Withhold 01 David E. Friedman Please make your marks like this: Use dark black pencil or pen only The Board of Directors recommends a vote FOR proposal 1, FOR the Election of the Director in proposal 2 and FOR proposal 3. 2: Election of Director 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance by the Company of shares of common stock pursuant to the terms of the private placement financing transaction contemplated by a Securities Purchase Agreement dated May 6, 2018, between the Company and each of the investors named therein, and the other documents and agreements related thereto, without giving effect to the caps on issuing shares contained therein. For Call</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><img src="gl3wrlsmluwf000003.jpg" title="" alt="" style="width:624px;height:482px;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#FFFFFF;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revocable Proxy &#8212; Genprex, Inc. Annual Meeting of Stockholders Monday, October 1, 2018 10:30 a.m. (Central Daylight Time) This Proxy is Solicited on Behalf of the Board of Directors <font style="font-weight:normal;">The undersigned appoints Rodney Varner and Ryan Confer, each with full power of substitution, to act as proxies for the undersigned, and to vote all shares of common stock of Genprex, Inc. that the undersigned is entitled to vote at the Annual Meeting of Stockholders on Monday, October 1, 2018, at 10:30 a.m. at the offices of W2O group at 507 Calles Street, Suite 112, Austin, Texas 78702, and any and all adjournments thereof, as set forth below. This proxy is revocable and will be voted as directed. However, if no instructions are specified, the proxy will be voted FOR the election of the director nominee specified in Proposal 2 and FOR Proposals 1 and 3. </font>(CONTINUED AND TO BE SIGNED ON REVERSE SIDE) <font style="font-weight:normal;">Please separate carefully at the perforation and return just this portion in the envelope provided.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:10pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gl3wrlsmluwf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gl3wrlsmluwf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )H QT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M20QK'&@1$ 5548  ["N:M_&,<_@_^W$MDFE\P6XM[>=75Y3((U4/TP6(Y(&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO*5&&Z\5T5% &7IN@VFE(BVTEUD2M-(TD[.TSL,$N3][MCTP*U*** "BBB@
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M;V^KI,T-PVCG3_/DVP9E@D$YB;?SP%(P>OXULMXXTA=;FTH_:#+$TD?F"/\
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M@!)QN SC/% &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '*^*XM-FU'2H]0M+Z9I&DBB-M(%1@0'='RPRI$>?PK)M
MM/\  0NVQ>1+-=(2T#71QLE4C;@'&")O_'ASTK>\2S:3#=Z6^IWS6K12221
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M:LZEH4VH7OVA9DMV>(1N\8(8KALJ>SJ<]^G)'6J(T76@C>7=,K,A<%I<@/G
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M\2"L5JRZ#>2FX#%3$VY. ",-C!ZX/ISUJW/XSNDAN@NDM'<01D[&<MN8/L.
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M$>GINN9 (B\Q "9<$M\O#?NSQ[]>M '4T5SL/B2:30;W4'M$6>V&3;^801D
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MNP%MA8CKA<]^ /:I[]+;3M8L1'HU@8[AHX/-)"R$YX"@+R%"ACDCH,<BF_\
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M/,!0#<"N1D$<5F1_#^%+'["-8O\ [) ZR6$0V8M&63S%8<?.0W'S9XX]Z5?
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MLQ5 2%7)X'I71T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLZ0JC-EU&&((C Z#KM9_^!BJ<0\1HR3"6\>0LA\N15V99Y%8'CH%$9]LY[T
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M XPV#TR*M54T^P&GVZP)-(\:(B*KD80*H7CZXSWY-6Z "BBB@ HHHH ****
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M1110 4444 %%%% !1110 5YKK7CI[#Q+-%)XDTK3;-)6B%O=P,[L% !<;?\
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M?VAC"(Q\FWYB<NWXX3_OFJ+^#&FL%M9KU>$C0LD9&0D;H.^>=X/7L?6NMHH
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M27"[@L)^YG&TD^N1SQ3XM4OYKZYL+J(7,)O#$%>+[T9D(('LB@-GN#0!4O\
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M0M,$;@?.7IZ]>E7*Y9O"(.X![< JH'[KIBW:+^;9KHK**2"SBAE*EHU" KW
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M0!1;Q!#E0@VG&,C'IVJ2H[?)MHB<9V#.&W=O7O\ 6I* "BBB@ HHHH ****
M"BBB@ HHHH **** "N<N-(UEM=U.].K&73)['R8=-\L#9+C[V[W_ *^U='7.
MW5QXB_MK4XGM;5=#6Q+6]PDA\XS8Y!'IU_(4 8$FFZV\$,]A:W6GKY$$$L<:
MH)7= V'X<#:"RC))Z="*D6PU^REAAT^VNXPLMR2[3[D)=I2"06QCF,YP3],'
M-2#4-8T7352%8XY7$#$23/)&N8V/5ANW.RX( ],<FM"SUS4;61+6:Y\]Y+@H
MI>+YLF[V,O']V,@^P(- $T.FWYO;>\AAU"+RQ&JBXN-S[?/!<-\QR-FX@$G
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MZ?3->:UE;SKPW+O,Q*7! R(2(]HS@#?V'?K6[HD=Y;?:;>Z%PR^;NADE??\
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ML4:M%YCI(26'[Q$*C'^]G)'3''>K1\37AT5+F.&V\\22I(NPE,)$T@ (/.<
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M)&5VQFU 5\C_ )[#))'H>U=17*^+F07%J&1O]6Y9_+W@KQE0/+?YCVZ4 =-
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M*PQU8C!_#';I0!IQG=&K'J0#3J9'$D0(08!)8C/<T^@ HHHH **** "BBB@
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M"Z2V&YE .YHSUR3^))''-2P>*M"TZ.WL+<R>4J$1[5!^50V#UR<[&P<?7&:
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M@A'[TGE0JC^(,<<]SQ5RQU[28KC[):6$UN3*JS!+=46*1V*@/@]25ZC/4<T
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M<8 QCTZ4 <KHOB.349[47-O"L<J'YV;+*2@;KC&.<5U>Q<$;1ANO'6D\J/\
MYYK_ -\BGT 5Y+&UFGAGD@1I86+1L1RI(Q_(XJ;RTPPV+A^6&.OUIU% #?+3
M^XOY4GDQ?\\TZ@_='4=#3Z* &>5'G/EIDG/W1445C;0W4ES'$!-( K-DG@=
M/0?2K%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->
M(;Z]L+Q3#J9A1XB4@6T5RQ!Y.YF Z')SP "372US'BFVN[R2%;:UNG"!E+1
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M6T27<L4GF"<QB1%\]D;>"5 Z G^''O0 E])X<MHUT*[B9(K6))(XPDA #;E
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M5,:E?ND9'':N6O\ 1-(=K6'[7;A8&MXI?.G&X*A9E4#U;<R\]0:ZN@ HHHH
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M,2W]V]N]U^X9%"(7(;EG7JSG@>M "V'Q,TB[>82P7, CB5@3&6+/WCQC[P.
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MF>";W3=/>*WN8+6[+LJ30NQQ'Y)0<'ONVMCVZ\5IV'AV\B\-'3;J=7=[E96
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MGM9S([L(VG<)EXPNXD+G(8%@,'.X\YYH FL/")>UM[DW=J;A!A-EN'A*_/\
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M5WD"I,X^8JZ@X &.J'J?N]\"@#2M?#D-OHRZ-+=K+NG6Y :,<JDB,5"DDE>
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MJ[SSV<T4:_V9.-S,A 'W/4UT.@QR0^'M,BE1DD2TB5E88*D(,@UH44 %%%%
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MLH+O@-R-N<G(W<>E+<^'KFR$D @N;]&@;[&T,OEK;3EF)(!;Y1RN#DX"D?4
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M4I9(SY=H3,?O8XV@\T[_ (6+H1LVN(Q>2$2!%A6W/F.#%YN\ _P^7\V?3WH
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M>(=9U*QEL4@6TSRDNYHR)'39(,<.0F[ SPPH ZVBBB@ HHHH **** "BBB@
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M,'_'O'C^Z/X=O;T[?2I*K:?<V]Y80SVLADA9!M8G)...?>K- !1110 4444
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M_)1F 9PQCYZC (SU&:Q;[X8Z??375P]Y,+B=YV$@1?D$LR2D#Z;,?1C7<T4
M94MIJPEC,.I@J;T2N'A7B#&#$./7G=UJG+X:G/B6[U:WU5X$O(HXKB 0J20@
M8 J_53\Y_*NAHH \]B^%4$6CW.GKK-QBYDC>1_)3Y]B%,D=VZ-NZA@#4^H?#
M*TOYIICJ4I=Y_.4SP),%S"L39###$A 03T/K7=T4 <FW@6W.\+?3!6U*+4 -
MB\&.-8PGT(7-3MX.A;P39^&?MDOE6P@ GVC<WE.KCCISMQ^-=+10!R=]X&@O
MM1NKQKZ5&N+Q;HJ$&%(MV@V_3#9^HK,D^%EF]LL?]H.TD;1,C2VZ2*-D @Y0
M\'(&>>AKOZ* ,K3M.NK1I[:2Z\S3Q#%#;1; K1[5(8DJ!UX^F#C%<RWPSMIK
M2>.ZU.>YG=;=(YI8E/RPL6C$@_Y:GG!+<D<5W=% 'G\7P]E77K0M>8TRUM[?
M[D:(TTL<TDF-J@!%RPZ?3WJ;3?AG9Z;?Z==K?M*]FD:$R6\;,XC9F3#$93[V
M#CK@=*[JB@#AK/X:VUG/:RKJ<[&WDAD ,:\^7/),!^)D(_"JW_"J;0PXDU.2
M62-D,!DMT9$"O(^&3HX)E;KZ"O0J* ,#1?"\.B7_ -JBN7D/V"&RVE%48C9S
MNPH !.\\ 8XK*/P]61[F6?6KR>X/E?99I55FA$<WG(&_YZ8;U[#%=I10!@:%
MH-SH)M[6&^,MBD<K3*Z*&DG>3>7&!P.6&.G(]*RY? 3W#:N)M8D>/4IQ<,?L
MZ>8CJRM'\_4JFT +TQGUKLZ* .8MO!L5O#IH:^EDEM-1DU*20H!YTKA]PQ_"
M,R'@>E5M&\"'0?M3V6L3K.\"VUO*T*'R8Q(SX(QAV)9OF-=A10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %97B"WL+O3?LVHSR0V\K8+1MC.%)P>",
M8!Z^W?%:M4=6T_\ M.Q^RDJ%:1&8G/ # \8[\8H P(8/#BM;P)>S\KY,:;V
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MX/TQ[0VQ:X\LJ5XDYQF0^G_35_TI[>%-->2XD;S3+<_ZZ3<-TAQ@$\>G''%
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MQKYVV,J5^?\ B79STZD1J#]/>GW_ (9L-1O)KF=IMTT?ENJN ,<>W^R*V:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.3N1"N1VR#T..HJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/4T /;Q'HZ-J2MJ$.=, -Z <F $9&[\*9:^*-&O0OD7R,6F6 *RLK;V!*C!
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MOO;YOWH);)!SGGUI(-!GL_%%QJD%UHLLMQ<MY9DEE5Q((@I0*K;3@KG&,XH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M275I;ZDD;2@6LF#' ZQ29-MERI_N;Y0.>=I]ZF?QMXF!VBTC5C8&8EK60 .
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M)L$:B/;LP-NWICVIU,BBC@A2&)%CC10J(HP% Z #TI] !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Y/X \!>%]=\*C4-3T>"YNY+NY#RNS9.)G Z'T
M KUBN*^%/_(B1?\ 7Y=_^CWH D_X57X'_P"A>MO^^G_^*K=T/P[I'ANUDMM'
ML8[2&1_,=$)(+8 SR3V K4HH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ,?7_#&E>)X(8=5AED2%RZ".=X\
M$C'52,UA?\*H\(_\^5U_X'S_ /Q==K10!YC-X5TGPM\2/"/]DQSPBY:[$P>Y
MDD#!8LCAF/J:].KB_$__ "4?P1_OWO\ Z)%=I0 4444 %%%% !1110 4444
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M.3L&WDXZ?>'7KFKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV?\ WTW^%&=4_NV?_?3?X4 7:*I9U3^[9_\ ?3?X5:B\SRU\T*),?-MZ?A0
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M44 %%%8/@_7Y?$WAY-2F@2!VGFBV(Q(^21D!R?7;F@#>HHHH **** "BBB@
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M<!02/?.#^&<4 17UIIR*L4<TX>;:6*(7+(QZ#_ZU33-HLELS[V98!YXV@Y(
M"Y&1R. /J*>;_2P\<AM&#QQ@*=H^0 $XZXX"D\?_ %J@EN]&:*0+8AU0 E<
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M^V:8(_DL6D11M48&6#9SC)YZG/XTR"YTB[G@C@LPWFR?,Q& ,*S#/K]T\=*
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M0H,2$(,*-H^7C''IQ4E% $3VMO+GS((GR,'<@.1Z4IMX64J88RIZ@J,&I**
M(GM;>7'F01/@Y&Y <'UH%O K*PAC#)G:0HRN>N*EHH C%O"O2&,<D\*._6D%
MO #D0QCKT4=SD_K4M% $$MG;S)(KQ+^\&&(&"?QI8[6WBCC1(4"QC"#:.*FH
MH K1V-M%/+,D2B24!6/J!V^E3"&(,K"- R]#M&13Z* (([*UBB,26\8C))*[
M1@Y.32BTMQ(L@A0,H(!"],]:FHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gl3wrlsmluwf000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gl3wrlsmluwf000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )H QT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTS$NYW(0>7)- '05C:KXCATV_CT^*RO+^^>(SFWM$4LD8.-S%F4 9X SDD'
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M20/Q- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;;*P4[758]Q"[OO+SS5VP\8K>MIX.G21)=V4UT9&F78K1%5= >^"WWC@<?D
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MW'()QCZXZ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK$_X2W1L9%T2/+,N1&V-@D$>[.,8W$?ASTJ2V\2Z==SPP0M.TLKE50P.&&
MIW$$?*I#*03ZT :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KNR
MBO#;M*7'V>83)M/5@".?;DU9KG-?T[4+O4(WMTE=/*"0M'<>6+>7=S(PR-PV
MD<<]",?-0 K^%])U"S4),TL:AE1P4D4'S"Y.""I(;(P01VJU/H=JNEVEHMW-
M:BUDS%/&45@S!D/5=O.\C@=2,<XK#NM!U&W\'Z9IUA!(LUOG?%%. .0WWOF7
M(W$'(;(/(SC%0ZCI.O73-!)9RS0),TS%+P*)09H7"KR""%5\$XQVZT ;7_")
MZ;#9QQ>?<JMN?,20R#*,$50V<=1L!^OMQ4$?A72)KJ&47;W%Q&[2L[F)W?+F
M3D[?E 9OX<<''I63)X>UF:6.,PS?9GCD01RW65AC8R80D-G< R]G!X&1MR2T
M\/:G:3?;$L'6588511<@L%22)FCY;'(5_;KDC/(!LR^&-*>>T1[R4-:PB"./
M>FX JP!SMW D%L@$ [>0<57M?"LXOS'<2%-.A1U@2.;)):5),XVC;S'SDM]X
MXP.*S1X?UYY+NZBA:TO+IQ(9/M62H!N,*2#U >/! P,Y[5*WA_5IFFDBCNK:
M%8F-G;/?$M%)F,@DAB#DAR,D@<^N* -:?PAH[ZA]JFR7G=MZN$/FDLS[<E=P
MQEN%(XZYQ5B+PS;I9W]M)>WTZWL2Q.\DHW(JKM 4@#'![YSWSDU'K5E-J\&F
M7%O;N)H+HR+O8 Q?(Z!R,X."5..>*J6&GZM:Z3J0@MI(IGME6&&>\,A:<!M[
M[P> V5QR#QDXS0 X>#(8ID6"]N(K=DF$ZIL4OY@B4J %PJD1]@"">,4MAX4C
M%O#,VH3F:)Y)+.2%E*VRNY;]WE>05(!W;N..E9=GH>LK,([NVNI+7S?W"I>^
M5]GSM)8@.<C[PVY;&".C9JQ<Z-JJ^$-(TNSM/+:&+RYD6;E&"$ @AP"-W.<G
M''RF@#67PGIZ!\27'[R%X6)<$D.,,>G4YS]:3_A$[,SVTAN+DK;S&>-#LX8O
MOX;;N SG.",@X.0 *J>&]/UBVU2:;45E*/#AWEF#DR<8VX;!&-W)52.@W YK
M(T+1]4NXK"<I=0P'+S&>[9S*X639)C=G:"4&WC/ (PM '6W.A6ETEX'WAKJ5
M)F<8RC($"E>./N*?K5-/#%FTD4\5]=[K9F6T9)%/V49(=4^7!!^Z=V3@ <8K
MG+G0/$$MO$+6&X@D4(9M]_DRD!O.P<G_ %N54'C!&[Y2,&>30_$+:DTB2W"P
MEY&AV3 &%"\AVD[C@D,O(5N@Y&* -B7PKI$&E_9KN>8VJB,,TTH&=L9C&XX[
M@\^I_*F+X2ABO--\LJ;>UG:Z=L+&SOM 5=J*J[<A6^J+5:WT*]N?#/V&]M_G
M%]#-&LDF2$62-F+ .P'1S@-@]< G%16>AZJTMLMQ%<1PK)$;L->%O/=0^^08
M;A22G'&>X&V@#9U/0]+U74C+/.ZW)MWMBD<P4X8'G']X!FP>P8^M10>$-/MX
M+B)9)RL\4L3 ;% $B(C;0J@#B-> ,=>*RM5\+W%YKE[<1VSA)6,J2I<E,OY&
MQ>AR,,/IT/..+6D:7K</B1[N]FE:%E;<=PV,"!M7&X\J<_PCJ>3F@"]?^$]/
MU&Z:YF+^:\C.251^&5%*C<IP/W:\CGK@C-27FA6$ND+I<LSQPO<&1,LN6<N9
M-N""&&<\$'@?C6(^CZU=7D=M/#,MG',_F2"[QYR-/OX"G( 3CGW%5!X>UTM:
M[DE-Y&6\N\>[W+"GD.BJ4S\Q#L#G&><YR* .AB\):=%8M9EIY(7V!@[#D+(\
M@' '&78?3%/A\/VL<&H6<M]=7#7L(CE,LBEUC"E!MP!CC/)!R:P+;0-9^S.9
M3>+MBF\F,7(1HY"(@"/G8<D2'DGDGIGBK<6E]IL%I+JV8[$#RWA^V&(OAI64
M%MY"D J<;L<  G % '1Z]X9CU2*X6W(A>[2*"=@VS;&CEMRX&=XR0.1UJ.7P
MAI,4\UV\\L2N7S\R*%#E3C=MR0"HQDG X&!Q6+9Z'KSZ/'<0RW,5]-!MWR7+
M$JIMD !!/!\P9S@'//%,F\.ZU-8K%);SSH6'D1-<B/[-^\4DL [!E(!P,OC&
M/XN #KI-"MI+=HTEN(G-T;M)8V >.0]2.,8P2,$'@D57;PO;,IS>7OF2!UN)
M?,!:X5B"5;(X'  VXP,@8HUM+S4]*A2SMW(>X F1FVMY8W D ,N><'&[H<\D
M8KGHO#_B!M-6222<:D2L;L;TD&(6^U@,' )D'7&<D&@#>7P_I*HB^>QC@81;
M3(N ?,WA3QU)8#'H0*;8^$K32T5K&:2.:)6$+;(P%RI49"J-V,]3DGN36?!H
M$S:!=6\FFR('U2.ZBMFN0[^6LD9Y;=C.%;C)'09J?3=%U!FO(;SSX5GMGAN)
MC<E_/E8\2H,_)@9_N]0,?** -/4/#EEJ6HP7T^?/B55)"(=X5MP'S*2N#G[I
M!YK.MO!NG1O]KLK^ZCGY\NXB:,E>6R<[2&/S,"6R3W.0#5 Z1K\T:W%W'(]Y
M,AXBN]BVTPVJLAP0&&%W8&>21@Y-1:?X<UBRN=,2,20V]N5&V-P53$KF0G+]
M'4CC:Q[?+@4 =-#HME82I=F:8>2[REI9,C+*%8L3[+GKUS51?">E33RW4<TY
M\U[AF*2C;F4;7'3MSCT)-9?B#2==OM6N7MH6^SLC1*1/A7C:!EP06_YZ%>-H
MZ Y)R*=J&C:M_8-K;VD4AGCN+B0QI, IW.[(6^93W4Y!RI['I0!K0>&]/*RF
M.YGD5W .)%PI64R8&!_?SG//:I=0\.6^H3RS_:;JWFD()DA905PC(<9!ZJY_
M0C%84F@ZK:I=364+&:Y:X,Z?:6*L&G1EVC<!G9YF!E<YP2,U770-?-C<%FE$
MB;(XD\_<6A$TC,@&\#E#&.6'3;G'- '20^&[6T$SV[R&22W, \P@KC:J\X'H
MB_K5*'PS!8Z?!+=:M=1W<$21&],B J@7;L&5QMY[C.><YJGHVDZW::S92W(G
MDB2+;(\LX(5=I^48;DYV\$,.-V[/%1:CX>U'4+UTEMY9(S=B661[H^7-$)59
M%"9^4H!Z#[IQG=0!K#P7HXE#".4)YF_RM_RD>5Y>SUV_Q=?O<YJ?2O#%EI,T
M<L#R-)'N )5%!#!1@A% . HYZ]<UM44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %86L:[-IU^L$,=L5CA$\OGR[&D4MMVQ^K?7U4=\C=K)O+_3A
MXAL=.NK8/=/%)<6\SQ@K'MP" QY5B"3] : .?G\9:C%&NRUL)7:W-V"D[%1'
MY;OM)Q]_Y,>F#GMBI+CQ9JMO++ ;*R:6#+2?OF"E?W.T [<YQ-R<?P^_%_2M
M:\/7UI$\4,-L+LR,(I854MRR%FQP-P4XR<D?C3I_$>@J8F 2;[1Y@W+#TV*'
M.XD< @*03P>#TH IGQ5>QAUD@LP]J6^TCS6'FXD,>(ACD\9P>Y4=\BSIGB*\
MN+2ZFN[6W4QV27L2QS8!5M_RLS  'Y.O3GVS5@ZSX<EWRF:T<VDF[=Y>2KLQ
M7*\9)+ CCOQ4XU71(]+AU!)K?['<*$BD1,^8.>  ,D#YCCMR?6@#G$\6ZF]Y
M""+)%*-$\3;EVRF2)59B1P ).@SG(YYX==^+[XV-XT"V4,EM"X=VFYD?,BAH
M<C# %,X/7D=N=&+5/#[:3?W$5C%]ATYV@)6W4(V0I;9VVG(R> >O3FD76=#\
MZUBO=/6TD$$AB,T*,B1@*"%=<KM(<# //(Z\4 21^));C05U"*U6*26Y^S1Q
MSO@Q$MM_>\?*P/51[#/>J>G>(-4N?[>NG6"1+*W'D6\.2K2+Y@8AL98,5&/;
MMGDZ%UKOAZ&QDEDDMWCNE>1H]@S*5^4[@1URNWYL<@"A?$>AV=Y#:!XX'EC
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MT?+GA]Q(.!USV(ILD?B.YUF1=FH6]K+.4D*2\*HFCP02> 8]_P!T#K@DD9H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4)+:T%A?N4A0.?-CRK%&8]#G;R!C;GJ<&M]!9B^FE5X_M31JLGS\A%)(XSP
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MRRD8QP,$U%#XT@^R_:;BSN5ME0E[D*NW>(O-VA=Q/W<\],\5M1Z+IT2HJ6P
M3R]OS,<>6Q9._8D_G3$T#2T@\@6:>5NW;"21GRS'W/\ <)% &/)X\TZ*Q6=H
MG\PRO&8A)&?NJK$AMVUN&7@$G)QU!KIX94G@CFC.4D4,I(QP1D5GMH&G/;+
MR3L%<N'-S)YF2,'Y]V[!&!C..*TE4(H51A0, #M0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<IXWDL5@L5OC&H:1@C2QQ.JG&,XD('?MSC/;-=77,^,;B]MH+22S-P
MN')D>(' ' YVHS="3P.QSV% &SI#F31;%VV[FMXR=L>P9*C.%_A'M69KWBA=
M$N3"+1[EDMS.P1@#RZQQJ/=G;&3@  FM'1(I(M#LDE>[>3R5+&\;=,"1G#G
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MY?0QW*W*M<SEG#+T&[^[U&/0F@#*TWQK>7VOII,UA96LP,2RQ274AE4M$LC
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M:;B2Q[L6=LGT K6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\9M;-
M;VD%PL3>:S!5ECC(.!SS(Z ?@<_E745R'C.572.*XM+CRHV#),L6Z-B1CYFW
M*(P#W;CF@#>T*&[@T6UCO)X9Y5C4!X8A&I7' VJ2HQTXX]*T:S= M#9:+;Q&
M59,KO!5BP /. <G(]\UI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8OB'5+_3$M7LK;SU>0B7Y
M-V!CZ@#ZY[8QSD;58'B>XMK9+5[C1UU'YFP7CW+%QR3A6(STZ?C0!K:=<?:]
M.MKG$8,L:L1$X=02.0&'!Y[U9K(\,7$-UX<LI8+&.Q1HQBVB4A8_8?*,CWQ6
MO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5SGB\Z@+2W-A#</A\R- TN0..-L;J3D9Y[8]2*Z.N
M7\73S6+6MTFIW5O&Q,;6\#H&D)X!&Y&Z$\]NGX@&]IBE-*LU:V%L5A0& '/E
M?*/ES[=*M56TTRG2[0S2K-*84WRH<AS@98' X/7I5F@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKF_%]M#<6EN924PY D6WDD*YQCE'4KR >O4"NDKE_&48>.Q8/9^:)'5([QAY
M;Y7'W2""?0\8S[XH T_#=TMWX=L7%L]JRPJCP-"T7EL  5"MR .WM6K5+1P!
MH>G@+(H%M'A9'WL/E'!;N?>KM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>-2J6UG*\"NBR',
MC730A"1Q]UUW9]SVKJ:YCQB D-G.EY:VLT;.$DN6X(*X8!2C DCVX_,$ UM"
M6Y31;2.[MXK>:.,(T4*X1<#HHR>*T:HZ*%70M/5(7A46T8$;DED^4<$D DCW
M J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5S_ (IU:[TE+-[:2"-7D/F&9XT! '3+NH]>G/ [
M9KH*YSQ;>75M#:QVMQ-;&5G#3)"9% "YP0$8\]CQT_"@#;L99)]/MI9C$9'B
M5G,+;D)(YVGN/2K%9OA^>&?0+%K>*6&-8$012AMR8 &T[@"2,8SWK2H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ -G1Q,NAZ>MP)!,+:,2"4DONVC.[/.<]:NU6L#(UE$\DWG,ZA]V5(Y Z%0
M1[XJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5SWBFQNK^.TCMH[N0!F\Q(&0*5(P0VYEQGID9
MX+?4=#7/^*C,(+8PZA-:?,V1'%*_F''&?+Y&* -'1/M(T.R6[AFAG6%5=)I%
M=P0,?,5X)^E7ZRO#<-W;>'K&*]D>2X6(;VD8LXSSAB222,X)S6K0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5@>)]-NM4CMHK;[&0K$R?:%4E01C<NY6&>O;J0>@(._7*>+[*SG
MGL9#917%_P#.L0EAC=2@&6W;RHX!R!GN?>@#H=-MC::=;PNL(E6-?-,"!49\
M $@#M5JJ6C"$:'IXMF=H/LT?EEUPQ7:,9'8XJ[0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/C
M+[,]G;075I<W$;N2!"^T*0.K<'\.*Z:N6\;).;.U>%+:8(S;H+NX$43_ "]3
MR,D=OK^( -;P]<3W.@63W22)<")5E60@MN '4CC)Z\>M:=4=&D\W0M/D\R67
M?;1MOE(+ME1RQ'?UJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5C>(FN5MX3;:=%>D.<K)")-O
M'4#(Q6S7/^*KBRA@MA>Z4-01G; 9<JG')/!Z_2@#5TNY:]TVWNF,96>-9$V
M@;6 ([GUJW69X?U!=4T*SNUMEME>,8A4Y"8XP.!Q6G0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5S?B][]+2V-C#<OB3,C0&4E1QD;8R&/&3Z<>I%=)7-^,+B_M[6V:RNG@'F9?
MRP=S8(.,A& &-W4=QZ8H VM,7;I5FOV;[+B!!Y&<^5\H^7/MT_"K55=,EDGT
MFSFFECEED@1GDC!"N2H)(!YP:M4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UXTN'MM.@9;I+<
M&3:7^UM"_/\ = 90Y]BP%=+7+>,X#=1V4,/F_:F9R@BX;: &8[BZ 8(4\D]!
M[T ;VF1I#I-G%&,(D** 5QT [9./S-6ZSM!"C0K+RY4DA,*F$I$8QY>!M&TD
MGICJ:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<MXWTG4]5T6YBLY?-A:'8;$6Z,9G)&
MTAV8;,'!R.1C(R0!74T4 9?AVRU+3_#]E:ZQ?B_U"*(+-<!<!S_7TSU.,FM2
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gl3wrlsmluwf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gl3wrlsmluwf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! 1\# 2(  A$! Q$!_\0
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M>_V-KEY),)VS;W,\A8AO[A8]CV]^.]2L/)T^>+N5]82GR25CV:CZ<UX/X_\
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M&G_'])]:**[,'\9P8[X"CX5_X_T^M>M+T%%%7C?B1.!^ =1WHHK@/1%HHHH
M**** "BBBD 4444=0"BBB@ HHHI@)2T44 )1112 6DHHI@ H-%% "T444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
